



## Clinical trial results:

### **Efficacy, safety and tolerability of tofacitinib for Treatment of polyarticular course juvenile idiopathic Arthritis (jia) in children and adolescent subjects**

#### **Summary**

EudraCT number	2015-001438-46
Trial protocol	GB BE DE ES PL
Global end of trial date	16 May 2019

#### **Results information**

Result version number	v1 (current)
This version publication date	01 February 2020
First version publication date	01 February 2020

#### **Trial information**

##### **Trial identification**

Sponsor protocol code	A3921104
-----------------------	----------

##### **Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

##### **Sponsors**

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

##### **Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000057-PIP60-10
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 May 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	16 May 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To compare the efficacy of tofacitinib versus placebo for the treatment of signs and symptoms of JIA at Week 44/End of Study (Week 26 of the double-blind phase) as measured by the percentage of subjects with disease flare (according to PRCSG/PRINTO Disease Flare criteria) after Week 18 of the open-label run-in phase.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 June 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 15
Country: Number of subjects enrolled	Australia: 4
Country: Number of subjects enrolled	Brazil: 20
Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	Israel: 15
Country: Number of subjects enrolled	Mexico: 12
Country: Number of subjects enrolled	Poland: 1
Country: Number of subjects enrolled	Russian Federation: 19
Country: Number of subjects enrolled	Spain: 3
Country: Number of subjects enrolled	Turkey: 14
Country: Number of subjects enrolled	Ukraine: 24
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	United States: 89
Country: Number of subjects enrolled	Belgium: 1
Worldwide total number of subjects	225
EEA total number of subjects	6

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	86
Adolescents (12-17 years)	139
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study was conducted in the 14 countries from 10-Jun-2016 to 16-Jun-2019. A total of 225 subjects were enrolled.

### Period 1

Period 1 title	Open-Label Phase (18 Weeks)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Tofacitinib: Open-Label Phase
-----------	-------------------------------

Arm description:

Subjects received tofacitinib 5 milligram (mg) tablets (for subjects greater than or equal to [ $\geq$ ] 40 kilogram (kg) body weight) or tofacitinib 5 milliliter (mL) oral solution (for subjects less than [ $<$ ] 40 kg body weight), twice daily [BID], orally for 18 weeks in open-label phase.

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution, Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received tofacitinib 5 mg tablets or tofacitinib 5 ml oral solution.

Number of subjects in period 1	Tofacitinib: Open-Label Phase
Started	225
OLJAS	184 <sup>[1]</sup>
OLERA	21 <sup>[2]</sup>
OLPsA	20 <sup>[3]</sup>
OLFAS	225
Completed	185
Not completed	40
Adverse event, non-fatal	12
Protocol Deviation	4
Insufficient Clinical Response	21
Unspecified	3

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Subjects initially received drug for 18 weeks in open label phase.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Subjects initially received drug for 18 weeks in open label phase.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Subjects initially received drug for 18 weeks in open label phase.

## Period 2

Period 2 title	Double Blind Phase (26 Weeks)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Tofacitinib: Double Blind Phase

Arm description:

Subjects who completed open-label phase and achieved at least a JIA ACR 30 response in open label phase, were randomized at Week 18 to receive tofacitinib tablets (for subjects  $\geq 40$  body weight) or oral solution (for subjects  $< 40$  kg body weight), BID, in double-blind phase for additional 26 weeks (up to Week 44).

Arm type	Experimental
Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects received tofacitinib 5 mg tablets or tofacitinib 5 ml oral solution.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Subjects who completed open-label phase and achieved at least a JIA ACR 30 response in open label phase, were randomized at Week 18 to receive placebo either as oral tablets, (for subjects  $\geq 40$  body weight) or oral solution (for subjects  $< 40$  kg body weight), BID, in double-blind phase for additional 26 weeks (up to Week 44).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects received placebo either as oral tablets or oral solution.

Number of subjects in period 2 <sup>[4]</sup>	Tofacitinib: Double Blind Phase	Placebo
Started	88	85
DBJAS	72	70
DBERA	9 <sup>[5]</sup>	7 <sup>[6]</sup>
DBPsA	7 <sup>[7]</sup>	8 <sup>[8]</sup>
DBSAS	88	85
Completed	61	38
Not completed	27	47
Adverse event, non-fatal	2	2
Withdrawal By Parent/Guardian	1	-
Protocol Deviation	-	1
Insufficient Clinical Response	22	44
Unspecified	1	-
Medication Error Without Associated Adverse Event	1	-

Notes:

[4] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only, Subjects who completed open-label phase and achieved at least a JIA ACR 30 response in open label phase, were included in double blind phase.

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only those subjects who completed open-label phase and achieved at least a JIA ACR 30 response in open label phase, were included in double blind phase.

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Population sets were created to show different populations based on set criteria.

[7] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only those subjects who completed open-label phase and achieved at least a JIA ACR 30 response in open label phase, were included in double blind phase.

[8] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Population sets were created to show different populations based on set criteria.

## Baseline characteristics

### Reporting groups

Reporting group title	Open-Label Phase (18 Weeks)
-----------------------	-----------------------------

Reporting group description:

Subjects received tofacitinib 5 mg tablets (for Subjects  $\geq$  40 kg body weight) or tofacitinib 5 mL oral solution (for Subjects  $<$ 40 kg body weight), BID, orally for 18 weeks in open-label phase.

Reporting group values	Open-Label Phase (18 Weeks)	Total	
Number of subjects	225	225	
Age categorical Units: Subjects			

Age Continuous Units: Years arithmetic mean standard deviation	11.92 $\pm$ 4.06	-	
Sex: Female, Male Units: Subjects			
Female	169	169	
Male	56	56	
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	0	0	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	5	5	
White	196	196	
More than one race	0	0	
Unknown or Not Reported	24	24	
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	64	64	
Not Hispanic or Latino	161	161	
Unknown or Not Reported	0	0	

## End points

### End points reporting groups

Reporting group title	Tofacitinib: Open-Label Phase
-----------------------	-------------------------------

Reporting group description:

Subjects received tofacitinib 5 milligram (mg) tablets (for subjects greater than or equal to [ $\geq$ ] 40 kilogram (kg) body weight) or tofacitinib 5 milliliter (mL) oral solution (for subjects less than [ $<$ ] 40 kg body weight), twice daily [BID], orally for 18 weeks in open-label phase.

Reporting group title	Tofacitinib: Double Blind Phase
-----------------------	---------------------------------

Reporting group description:

Subjects who completed open-label phase and achieved at least a JIA ACR 30 response in open label phase, were randomized at Week 18 to receive tofacitinib tablets (for subjects  $\geq 40$  body weight) or oral solution (for subjects  $< 40$  kg body weight), BID, in double-blind phase for additional 26 weeks (up to Week 44).

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects who completed open-label phase and achieved at least a JIA ACR 30 response in open label phase, were randomized at Week 18 to receive placebo either as oral tablets, (for subjects  $\geq 40$  body weight) or oral solution (for subjects  $< 40$  kg body weight), BID, in double-blind phase for additional 26 weeks (up to Week 44).

Subject analysis set title	Tofacitinib 5mg Open Label Phase
----------------------------	----------------------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Subjects received tofacitinib 5 mg tablets (for subjects  $\geq 40$  kg body weight) or tofacitinib 5 mL oral solution (for subjects  $< 40$  kg body weight), BID, orally for 18 weeks in open-label phase.

### **Primary: Double Blind Phase: Percentage of Subjects With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 44**

End point title	Double Blind Phase: Percentage of Subjects With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 44
-----------------	---

End point description:

According to PRCSG/PRINTO, disease flare: worsening of  $\geq 30\%$  in  $\geq 3$  of 6 variables of JIA core set, with no more than 1 variable improving by  $\geq 30\%$ . 6 core variables were: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range of motion accompanied by pain/tenderness), 2) Number of joints with limited range of motion 3) Physician global evaluation of disease activity (assessed on a VAS of 0 [no activity] to 10 [maximum activity]), 4) Parent/legal guardian/subject global assessment of overall well-being (assessed on VAS of 0 [very well] to 10 [very poor]) 5) Functional ability assessed using disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities), each question answered on a scale of 0=without difficulty to 3=unable to do, and 6) ESR.DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA.

End point type	Primary
----------------	---------

End point timeframe:

Week 44



End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)	29.17	52.86		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
----------------------------	--

Statistical analysis description:

In order to preserve type I error, each endpoint assessed sequentially using gate-keeping or step-down approach where statistical significance was claimed for the second endpoint only if the first endpoint in the sequence meets the requirements for significance.

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0031 <sup>[1]</sup>
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-23.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	-39.41
upper limit	-7.97

Notes:

[1] - Threshold for significance at 0.05 level.

## Secondary: Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Week 44

End point title	Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Week 44
-----------------	---

End point description:

JIA ACR50 response:  $\geq 50\%$  improvement in 3out of 6JIA coreset variables with no  $>$  than 1out of 6 JIA core set variables worsened by30%.6 core variables: 1)Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness),2)Number of joints with limited range motion 3)Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]),4)Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5)Functional ability: disability index of CHAQ: 30 questions in 8domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities),each question answered on a scale:0=without difficulty to 3=unable to do, and, 6)ESR. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)	66.67	47.14		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
----------------------------	--

Statistical analysis description:

In order to preserve type I error, each endpoint assessed sequentially using gate-keeping or step-down approach where statistical significance was claimed for the second endpoint only if the first endpoint in the sequence meets the requirements for significance.

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0166 [2]
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	19.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.55
upper limit	35.5

Notes:

[2] - Threshold for significance at 0.05 level.

## Secondary: Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Week 44

End point title	Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Week 44
-----------------	---

End point description:

JIA ACR30 response: >=30% improvement in 3 out of 6 JIA core set variables with no >than 1 out of 6 JIA core set variables worsened by 30%. 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5) Functional ability: disability index of CHAQ, 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0=without difficulty to 3=unable to do, and 6) ESR. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)	70.83	47.14		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: In order to preserve type I error, each endpoint assessed sequentially using gate-keeping or step-down approach where statistical significance was claimed for the second endpoint only if the first endpoint in the sequence meets the requirements for significance.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0031 <sup>[3]</sup>
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	23.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.97
upper limit	39.41

Notes:

[3] - Threshold for significance at 0.05 level.

## Secondary: Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 44

End point title	Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 44
-----------------	---

End point description:

JIA ACR70 response: >=70% improvement in 3out of 6 JIA core set variables with no >than 1out of 6 JIA core set variables worsened by30%.6 core variables: 1)Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness),2)Number of joints with limited range motion 3)Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]),4)Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5)Functional ability: disability index of CHAQ: 30 questions in 8domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities),each question answered on a scale:0=without difficulty to 3=unable to do, and, 6)ESR. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
End point timeframe:	
Week 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)	54.17	37.14		

## Statistical analyses

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
In order to preserve type I error, each endpoint assessed sequentially using gate-keeping or step-down approach where statistical significance was claimed for the second endpoint only if the first endpoint in the sequence meets the requirements for significance.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0387 <sup>[4]</sup>
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	17.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.88
upper limit	33.17

Notes:

[4] - Threshold for significance at 0.05 level.

## Secondary: Double Blind Phase: JIA ACR Core Variable- Change from Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Disability Index at Week 44

End point title	Double Blind Phase: JIA ACR Core Variable- Change from Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Disability Index at Week 44
-----------------	---

End point description:

CHAQ comprises of 3 indices: Disability, Discomfort, and global assessment of arthritis (overall well-being). CHAQ Disability Index: measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities-distributed, among a total of 30 items. Each question rated on a 4-point scale ranges from 0 (no difficulty) to 3 (unable to do). To calculate overall score, subject must have domain score in at least 6 of 8 domains. Scores of 8 domains were averaged to calculate the CHAQ disability index which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score=less ability. Highest score = score for functional area, minimum score = functional area is 2. DBJAS: all subjects randomized to DB phase,

received at least 1 dose of study medication in DB phase and had polyarticular course JIA. Number of subjects analysed=subjects who were evaluable for this end point.

End point type	Secondary
End point timeframe:	
Baseline, Week 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	49	33		
Units: units on a scale				
least squares mean (standard error)	-0.09 ( $\pm$ 0.04)	0.03 ( $\pm$ 0.04)		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
----------------------------	--

Statistical analysis description:

In order to preserve type I error, each endpoint assessed sequentially using gate-keeping or step-down approach where statistical significance was claimed for the second endpoint only if the first endpoint in the sequence meets the requirements for significance. Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0292 <sup>[5]</sup>
Method	MMRM
Parameter estimate	Ls mean difference
Point estimate	-0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.22
upper limit	-0.01
Variability estimate	Standard error of the mean
Dispersion value	0.05

Notes:

[5] - Threshold for significance at 0.05 level.

## Secondary: Open-Label Phase: Percentage of Subjects With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare criteria at Week 2, 4, 8, 12 and 18

End point title	Open-Label Phase: Percentage of Subjects With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare criteria at Week 2, 4, 8, 12 and 18
-----------------	---

---

**End point description:**

PRCSG/PRINTO,disease flare: worsening of  $\geq 30\%$  in  $\geq 3$  of 6 variables of JIAcore set, with no  $>1$  variable improving by  $\geq 30\%$ .6 core variables: 1)Number of joints with active arthritis (joint with swelling/absence of swelling,limited range of motion accompanied by pain/tenderness), 2)Number of joints with limited range of motion 3)Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4)Parent/legal guardian/subject global assessment of overall well-being (VAS of 0[very well] to 10[very poor] 5)Functional ability assessed using disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach,grip and activities),each question answered on scale of 0=without difficulty to 3=unable to do, and 6)ESR.OLJAS: all subjects who enrolled in OL phase of study and received at least 1 dose of medication in OL phase and had polyarticular courseJIA.n =subjects evaluable for this end point at specified time points.

---

End point type	Secondary
----------------	-----------

---

**End point timeframe:**

Weeks 2, 4, 8, 12 and 18

---

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: percentage of subjects				
number (not applicable)				
Week 2 (n= 184)	0.54			
Week 4 (n= 183)	3.83			
Week 8 (n= 175)	5.14			
Week 12 (n= 166)	7.23			
Week 18 (n= 154)	8.44			

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Double Blind Phase: Percentage of Subjects According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria With Disease Flare at Weeks 20, 24, 28, 32, 36 and 40**

---

---

End point title	Double Blind Phase: Percentage of Subjects According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria With Disease Flare at Weeks 20, 24, 28, 32, 36 and 40
-----------------	---

---

**End point description:**

PRCSG/PRINTO, disease flare: worsening of  $\geq 30\%$  in  $\geq 3$  of 6 variables of JIA core set, with no  $>1$  variable improving by  $\geq 30\%$ .6 core variables: 1)Number of joints with active arthritis (joint with swelling/absence of swelling, limited range of motion accompanied by pain/tenderness), 2)Number of joints with limited range of motion 3)Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4)Parent/legal guardian/subject global assessment of overall well-being (VAS of 0[very well] to 10[very poor] 5)Functional ability assessed using disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities),each question answered on a scale of 0=without difficulty to 3=unable to do, and, 6)ESR. DBJAS: all subjects randomized to DB phase, received at least 1dose of study medication in DB phase and had polyarticular course JIA.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Weeks 20, 24, 28, 32, 36 and 40

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)				
Week 20	9.72	11.43		
Week 24	12.50	31.43		
Week 28	18.06	37.14		
Week 32	23.61	45.71		
Week 36	25.00	48.57		
Week 40	27.78	52.86		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Week 20	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.741
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-1.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.82
upper limit	8.41

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Week 24	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0052
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-18.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.22
upper limit	-5.64

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0093
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-19.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.48
upper limit	-4.7

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0045
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-22.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.35
upper limit	-6.86



<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0027
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-23.57
Confidence interval	
level	95 %
sides	2-sided
lower limit	-38.97
upper limit	-8.17

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0016
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-25.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-40.69
upper limit	-9.47

## Secondary: Open-Label Phase: Time to Disease Flare

End point title	Open-Label Phase: Time to Disease Flare
-----------------	---

End point description:

Time to disease flare: time(days) from first dose of study drug until day of disease flare in OL phase. PRCSG/PRINTO, disease flare: worsening of  $\geq 30\%$  in  $\geq 3$  of 6 variables of JIA core set, no  $>1$  variable improving by  $\geq 30\%$ . 6 core variables: 1) Number of joints with active arthritis, 2) Number of joints with limited range of motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subject global assessment of overall well-being (VAS of 0[very well] to 10[very poor]) 5) Functional ability assessed by disability index of CHAQ: 30 questions in 8 domains each question answered on scale of 0=without difficulty to 3=unable to do, and, 6) ESR. OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with

polyarticular course JIA. 99999= Median, upper and lower limits of 95% CI was not estimable due to small number of subjects with the event.

End point type	Secondary
End point timeframe:	
Day 1 up to week 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Time to Disease Flare

End point title	Double Blind Phase: Time to Disease Flare
End point description:	
Time to disease flare: time(days) from first dose of study drug until day of disease flare in OL phase. PRCSG/PRINTO, disease flare: worsening of $\geq 30\%$ in $\geq 3$ of 6 variables of JIA core set, no $>1$ variable improving by $\geq 30\%$ . 6 core variables: 1) Number of joints with active arthritis, 2) Number of joints with limited range of motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subject global assessment of overall well-being (VAS of 0[very well] to 10[very poor] 5) Functional ability assessed by disability index of CHAQ: 30 questions in 8 domains each question answered on scale of 0=without difficulty to 3=unable to do, and, 6) ESR. DBJAS analysis set used JIA. 99999= Tofacitinib; Median, upper and lower limits of 95% CI was not estimable due to small number of subjects with the event And Placebo; Upper limit of 95% CI was not estimable due to small number of subjects with the event.	
End point type	Secondary
End point timeframe:	
Day 1 of Week 18 up to Week 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	155.0 (86.0 to 99999)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Open-Label Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Weeks 2, 4, 8, 12 and 18

End point title	Open-Label Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Weeks 2, 4, 8, 12 and 18
-----------------	--

End point description:

JIA ACR30 response:  $\geq 30\%$  improvement in 3 out of 6 JIA core set variables with no  $>$  than 1 out of 6 JIA core set variables worsened by  $30\%$ . 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0 [no activity] to 10 [maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0 [very well] to 10 [very poor] 5) Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0 = without difficulty to 3 = unable to do, and, 6) ESR. OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: percentage of subjects				
number (not applicable)				
Week 2 (n= 184)	45.11			
Week 4 (n= 183)	68.31			
Week 8 (n= 177)	79.66			
Week 12 (n= 167)	85.63			
Week 18 (n= 154)	92.21			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Double Blind Baseline, Week 20, 24, 28, 32, 36 and 40

End point title	Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Double Blind Baseline, Week 20, 24, 28, 32, 36 and 40
-----------------	---

End point description:

JIA ACR30 response:  $\geq 30\%$  improvement in 3 out of 6 JIA core set variables with no  $>$  than 1 out of 6 JIA core set variables worsened by  $30\%$ . 6 core variables: 1) Number of joints with active arthritis (joint

with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness),2)Number of joints with limited range motion 3)Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]),4)Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5)Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities),each question answered on a scale:0=without difficulty to 3=unable to do, and 6)ESR. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
End point timeframe:	
Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36 and 40	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)				
Double Blind Baseline (Week 18)	100.00	100.00		
Week 20	88.89	82.86		
Week 24	86.11	68.57		
Week 28	80.56	61.43		
Week 32	76.39	52.86		
Week 36	73.61	48.57		
Week 40	70.83	47.14		

## Statistical analyses

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.301
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	6.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.4
upper limit	17.46

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0108
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	17.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.05
upper limit	31.03

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0103
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	19.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.51
upper limit	33.74

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0025
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	23.53

Confidence interval	
level	95 %
sides	2-sided
lower limit	8.27
upper limit	38.8

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0016
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	25.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.52
upper limit	40.56

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0031
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	23.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.97
upper limit	39.41

<b>Secondary: Open-Label Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Week 2, 4, 8, 12 and 18</b>	
End point title	Open-Label Phase: Percentage of Subjects With Juvenile

End point description:

JIA ACR50 response:  $\geq 50\%$  improvement in 3 out of 6 JIA core set variables with no  $> 1$  out of 6 JIA core set variables worsened by  $30\%$ . 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5) Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0=without difficulty to 3=unable to do, and, 6) ESR. OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. n = subjects evaluable for this end point at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: percentage of subjects				
number (not applicable)				
Week 2 (n= 184)	20.11			
Week 4 (n= 183)	44.81			
Week 8 (n= 177)	62.71			
Week 12 (n= 167)	71.86			
Week 18 (n= 154)	83.77			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Double Blind Baseline, Week 20, 24, 28, 32, 36 and 40

End point title	Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Double Blind Baseline, Week 20, 24, 28, 32, 36 and 40
-----------------	---

End point description:

JIA ACR50 response:  $\geq 50\%$  improvement in 3 out of 6 JIA core set variables with no  $> 1$  out of 6 JIA core set variables worsened by  $30\%$ . 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5) Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0=without difficulty to 3=unable to do, and, 6) ESR. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
----------------	-----------

End point timeframe:

Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)				
Double blind Baseline (Week 18)	90.28	91.43		
Week 20	81.94	74.29		
Week 24	80.56	58.57		
Week 28	73.61	55.71		
Week 32	69.44	44.29		
Week 36	68.06	47.14		
Week 40	68.06	45.71		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Double blind Baseline (Week 18)	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8119
Method	Normal approximation for binomial
Parameter estimate	Difference in percentage
Point estimate	-1.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.63
upper limit	8.33

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Week 20	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo



Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2682
Method	Normal approximation for binomial
Parameter estimate	Difference in percentage
Point estimate	7.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.9
upper limit	21.21

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0034
Method	Normal approximation for binomial
Parameter estimate	Difference in percentage
Point estimate	21.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.26
upper limit	36.71

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0233
Method	Normal approximation for binomial
Parameter estimate	Difference in percentage
Point estimate	17.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.44
upper limit	33.36

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0018
Method	Normal approximation for binomial
Parameter estimate	Difference in percentage
Point estimate	25.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.39
upper limit	40.93

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0099
Method	Normal approximation for binomial
Parameter estimate	Difference in percentage
Point estimate	20.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.01
upper limit	36.81

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0058
Method	Normal approximation for binomial
Parameter estimate	Difference in percentage
Point estimate	22.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.46
upper limit	38.22

---

**Secondary: Open-Label Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 2, 4, 8, 12 and 18**

---

End point title	Open-Label Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 2, 4, 8, 12 and 18
-----------------	---

End point description:

JIA ACR70 response: >=70% improvement in 3 out of 6 JIA core set variables with no > 1 out of 6 JIA core set variables worsened by 30%. 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5) Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0=without difficulty to 3=unable to do, and, 6) ESR. OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA n = subjects evaluable for this end point at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 2, 4, 8, 12 and 18

---

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: percentage of subjects				
number (not applicable)				
Week 2 (n= 184)	7.61			
Week 4 (n= 183)	16.94			
Week 8 (n= 177)	36.16			
Week 12 (n= 167)	46.71			
Week 18 (n= 154)	61.04			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36 and 40

End point title	Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36 and 40
-----------------	---

End point description:

JIA ACR70 response:  $\geq 70\%$  improvement in 3 out of 6 JIA core set variables with no  $> 1$  out of 6 JIA core set variables worsened by  $\geq 30\%$ . 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5) Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0=without difficulty to 3=unable to do, and, 6) ESR. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
----------------	-----------

End point timeframe:

Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)				
DB Baseline Week 18	68.06	64.29		
Week 20	58.33	55.71		
Week 24	58.33	44.29		
Week 28	54.17	47.14		
Week 32	56.94	38.57		
Week 36	54.17	34.29		
Week 40	54.17	34.29		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Double Blind Baseline (Week 18)	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6348
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	3.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.79
upper limit	19.33

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7525
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	2.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.66
upper limit	18.9

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0908
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	14.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.23
upper limit	30.33

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4026
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	7.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.38
upper limit	23.43

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0258
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	18.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.22
upper limit	34.52

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0149
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	19.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.88
upper limit	35.88

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Week 40	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0149
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	19.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.88
upper limit	35.88

### **Secondary: Open-Label Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Week 2, 4, 8, 12 and 18**

End point title	Open-Label Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Week 2, 4, 8, 12 and 18
End point description: JIA ACR90 response: >=90% improvement in 3 out of 6 JIA core set variables with no > 1 out of 6 JIA core set variables worsened by 30%. 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5) Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0=without difficulty to 3=unable to do, and, 6) ESR. OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. n =subjects evaluable for this end point at specified time points.	
End point type	Secondary
End point timeframe: Week 2, 4, 8, 12 and 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: percentage of subjects				
number (not applicable)				
Week 2 (n= 184)	0			
Week 4 (n= 183)	3.83			
Week 8 (n= 177)	11.30			
Week 12 (n= 167)	20.96			
Week 18 (n= 154)	33.12			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Double Blind Baseline, Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Double Blind Baseline, Week 20, 24, 28, 32, 36, 40 and 44
-----------------	---

End point description:

JIA ACR90 response: >=90% improvement in 3 out of 6 JIA core set variables with no > 1 out of 6 JIA core set variables worsened by 30%. 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5) Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0=without difficulty to 3=unable to do, and, 6) ESR. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
----------------	-----------

End point timeframe:

Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)				
DB Baseline (Week 18)	33.33	38.57		



Week 20	34.72	25.71		
Week 24	37.50	28.57		
Week 28	36.11	27.14		
Week 32	38.89	22.86		
Week 36	38.89	20.00		
Week 40	34.72	22.86		
Week 44	34.72	21.43		

## Statistical analyses

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Double Blind Baseline (Week 18)	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.515
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-5.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21
upper limit	10.53

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Week 20	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.24
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	9.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.02
upper limit	24.03

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2557
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	8.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.47
upper limit	24.32

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2481
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	8.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.25
upper limit	24.19

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0356
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	16.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	1.08
upper limit	30.98

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0115
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	18.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.24
upper limit	33.54

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.115
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	11.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.89
upper limit	26.62

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0744
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	13.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.31
upper limit	27.9

### Secondary: Open-Label Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Week 2, 4, 8, 12 and 18

End point title	Open-Label Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Week 2, 4, 8, 12 and 18
-----------------	--

End point description:

JIA ACR100 response: >=100% improvement in 3 out of 6 JIA core set variables with no > 1 out of 6 JIA core set variables worsened by 30%. 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5) Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0=without difficulty to 3=unable to do, and, 6) ESR. OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: percentage of subjects				
number (not applicable)				
Week 2 (n= 184)	0.0			
Week 4 (n= 183)	2.19			
Week 8 (n= 177)	8.47			
Week 12 (n= 167)	14.37			
Week 18 (n= 154)	21.43			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Double Blind Baseline, Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Percentage of Subjects With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Double Blind Baseline, Week 20, 24, 28, 32, 36, 40 and 44
End point description:	JIA ACR100 response: $\geq 100\%$ improvement in 3 out of 6 JIA core set variables with no $>1$ out of 6 JIA core set variables worsened by $\geq 30\%$ . 6 core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range motion accompanied by either pain on motion/tenderness), 2) Number of joints with limited range motion 3) Physician global evaluation of disease activity (VAS of 0[no activity] to 10[maximum activity]), 4) Parent/legal guardian/subjects global assessment of overall well-being VAS of 0[very well] to 10[very poor] 5) Functional ability: disability index of CHAQ: 30 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip, activities), each question answered on a scale: 0=without difficulty to 3=unable to do, and, 6) ESR. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA.
End point type	Secondary
End point timeframe:	Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)				
DB Baseline	15.28	31.43		
Week 20	27.78	17.14		
Week 24	27.78	24.29		
Week 28	26.39	24.29		
Week 32	27.78	21.43		
Week 36	30.56	18.57		
Week 40	29.17	20.00		
Week 44	29.17	17.14		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Double Blind Baseline (Week 18)	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0207
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-16.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.84
upper limit	-2.46

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1254
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	10.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.97
upper limit	24.24

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.635
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	3.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.93
upper limit	17.91

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7732
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.2
upper limit	16.41

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3782
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	6.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.77
upper limit	20.47

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0936
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	11.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.02
upper limit	25.99

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2017
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	9.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.91
upper limit	23.24

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0858
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	12.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.69
upper limit	25.74



## Secondary: Open Label Phase: Change From Baseline in Juvenile Arthritis Disease Activity Score (JADAS) 27 C-Reactive Protein (CRP) Score at Week 2, 4, 8, 12 and 18

End point title	Open Label Phase: Change From Baseline in Juvenile Arthritis Disease Activity Score (JADAS) 27 C-Reactive Protein (CRP) Score at Week 2, 4, 8, 12 and 18
-----------------	--

End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 [no activity] to 10 [maximum activity]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 [very well] to 10 [very poor]), 3) Number of joints with active disease (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter [mg/L] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity. OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 2 (n= 181)	-6.35 (± 5.44)			
Week 4 (n= 180)	-9.89 (± 6.54)			
Week 8 (n= 175)	-12.47 (± 7.51)			
Week 12 (n= 163)	-14.33 (± 6.96)			
Week 18 (n= 153)	-15.80 (± 7.12)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Change from Double-Blind Baseline in Juvenile Arthritis Disease Activity Score (JADAS) 27 C-Reactive Protein (CRP) Score at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Change from Double-Blind Baseline in Juvenile Arthritis Disease Activity Score (JADAS) 27 C-Reactive Protein (CRP) Score at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 [no

activity] to 10 [maximum activity]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 [very well] to 10 [very poor]), 3) Number of joints with active disease (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in mg/L and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: Score on scale				
least squares mean (standard error)				
Week 20 (n= 70, 69)	0.27 (± 0.64)	2.33 (± 0.64)		
Week 24 (n= 65, 59)	0.83 (± 0.95)	4.46 (± 0.97)		
Week 28 (n= 63, 47)	0.51 (± 0.91)	4.36 (± 0.97)		
Week 32 (n= 59, 43)	0.16 (± 0.73)	3.46 (± 0.81)		
Week 36 (n= 54, 36)	0.34 (± 1.09)	6.55 (± 1.22)		
Week 40 (n= 53, 34)	0.85 (± 1.13)	7.11 (± 1.26)		
Week 44 (n= 49, 32)	0.03 (± 0.91)	4.39 (± 1.00)		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
----------------------------	--

Statistical analysis description:

Week 20: Analysis was based on Mixed Model for Repeated Measures (MMRM) with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0088
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-2.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	-0.53
Variability estimate	Standard error of the mean
Dispersion value	0.78

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0054
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-3.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.17
upper limit	-1.1
Variability estimate	Standard error of the mean
Dispersion value	1.28

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0039
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-3.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.38
upper limit	-1.32
Variability estimate	Standard error of the mean
Dispersion value	1.25

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0022
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-3.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.3
upper limit	-1.29
Variability estimate	Standard error of the mean
Dispersion value	0.98

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-6.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.42
upper limit	-3
Variability estimate	Standard error of the mean
Dispersion value	1.57

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0006
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-6.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.6
upper limit	-2.92
Variability estimate	Standard error of the mean
Dispersion value	1.63

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0027
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-4.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.02
upper limit	-1.71
Variability estimate	Standard error of the mean
Dispersion value	1.27

### **Secondary: Open Label Phase: Change From Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Week 2, 4, 8, 12 and 18**

End point title	Open Label Phase: Change From Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Week 2, 4, 8, 12 and 18
-----------------	--

#### End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 [no activity] to 10 [maximum activity]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 [very well] to 10 [very poor]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity. OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 8, 12 and 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 2 (n= 180)	-6.38 (± 5.52)			
Week 4 (n= 180)	-10.14 (± 6.63)			
Week 8 (n= 174)	-12.60 (± 7.60)			
Week 12 (n= 165)	-14.54 (± 6.90)			
Week 18 (n= 154)	-15.94 (± 7.17)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Change from Double-Blind Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Change from Double-Blind Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 [no activity] to 10 [maximum activity]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 [very well] to 10 [very poor]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity. DBJAS: all subjects randomized to DB phase, received at least 1dose of study medication in DB phase and had polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: Score on scale				
least squares mean (standard error)				
Week 20 (n= 71, 70)	0.62 ( $\pm$ 0.62)	2.45 ( $\pm$ 0.62)		
Week 24 (n= 66, 60)	0.92 ( $\pm$ 0.90)	4.33 ( $\pm$ 0.92)		
Week 28 (n= 63, 49)	0.64 ( $\pm$ 0.86)	4.22 ( $\pm$ 0.90)		
Week 32 (n= 59, 45)	0.26 ( $\pm$ 0.75)	3.67 ( $\pm$ 0.81)		
Week 36 (n= 55, 37)	0.60 ( $\pm$ 1.06)	6.26 ( $\pm$ 1.17)		
Week 40 (n= 53, 35)	0.73 ( $\pm$ 1.05)	6.35 ( $\pm$ 1.15)		
Week 44 (n= 49, 33)	0.09 ( $\pm$ 0.91)	4.50 ( $\pm$ 0.97)		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20: Analysis was based on Mixed Model for Repeated Measures (MMRM) with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value. All MMRM models adjusted for OL baseline CRP category.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0172
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-1.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.32
upper limit	-0.33
Variability estimate	Standard error of the mean
Dispersion value	0.76

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value. All MMRM models adjusted for OL baseline CRP category.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0057
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-3.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.81
upper limit	-1.01
Variability estimate	Standard error of the mean
Dispersion value	1.21

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value. All MMRM models adjusted for OL baseline CRP category.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0038
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-3.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.94
upper limit	-1.23
Variability estimate	Standard error of the mean
Dispersion value	1.16

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value. All MMRM models adjusted for OL baseline CRP category.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo



Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-3.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.47
upper limit	-1.36
Variability estimate	Standard error of the mean
Dispersion value	1.01

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value. All MMRM models adjusted for OL baseline CRP category.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0007
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-5.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.74
upper limit	-2.57
Variability estimate	Standard error of the mean
Dispersion value	1.52

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value. All MMRM models adjusted for OL baseline CRP category.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0007
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-5.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.66
upper limit	-2.58
Variability estimate	Standard error of the mean
Dispersion value	1.49

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value. All MMRM models adjusted for OL baseline CRP category.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0018
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-4.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.99
upper limit	-1.82
Variability estimate	Standard error of the mean
Dispersion value	1.25

### **Secondary: Open-Label Phase: Percentage of Subjects With JADAS-27 CRP Minimum Disease Activity at Week 2, 4, 8, 12 and 18**

End point title	Open-Label Phase: Percentage of Subjects With JADAS-27 CRP Minimum Disease Activity at Week 2, 4, 8, 12 and 18
-----------------	--

#### End point description:

Minimum Disease Activity is defined by a JADAS-27 CRP score less than or equal to 3.8 for subjects with polyarthritis, and less than or equal to 2 for subjects with oligoarthritis. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 [no activity] to 10 [maximum activity]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 [very well] to 10 [very poor]), 3) Number of joints with active disease (maximum of 27 defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP and value normalized to 0 to 10 scale). OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n"

signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Weeks 2, 4, 8, 12 and 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: percentage of subjects				
number (not applicable)				
Baseline (n= 184)	0			
Week 2 (n= 183)	2.19			
Week 4 (n= 183)	9.29			
Week 8 (n= 176)	20.45			
Week 12 (n= 165)	29.09			
Week 18 (n= 154)	44.16			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Percentage of Subjects With JADAS-27 CRP Minimum Disease Activity at Double Blind Baseline, Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Percentage of Subjects With JADAS-27 CRP Minimum Disease Activity at Double Blind Baseline, Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

Minimum Disease Activity: JADAS-27 CRP score less than or equal to 3.8 for subjects with polyarthritis, and less than or equal to 2 for subjects with oligoarthritis. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 [no activity] to 10 [maximum activity]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 [very well] to 10 [very poor]), 3) Number of joints with active disease (maximum of 27 defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP. overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points

End point type	Secondary
End point timeframe:	
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)				
DB Baseline (n= 72, 70)	48.61	47.14		
Week 20 (n= 72, 70)	45.83	35.71		
Week 24 (n= 72, 70)	47.22	34.29		
Week 28 (n= 72, 70)	47.22	35.71		
Week 32 (n= 72, 70)	40.28	32.86		
Week 36 (n= 72, 70)	44.44	30.00		
Week 40 (n= 72, 70)	45.83	31.43		
Week 44 (n= 70, 70)	45.71	32.86		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Double Blind Baseline (Week 18)	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.861
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	1.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.96
upper limit	17.9

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Week 20	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2173
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	10.12

Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.96
upper limit	26.2

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1135
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	12.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.08
upper limit	28.96

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.161
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	11.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.58
upper limit	27.6

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3571
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	7.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.37
upper limit	23.21

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0716
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	14.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.27
upper limit	30.16

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0746
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	14.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.43
upper limit	30.24

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Week 44	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0773
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	14.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.57
upper limit	30.3

### Secondary: Open-Label Phase: Percentage of Subjects With JADAS CRP Inactive Disease Activity at Week 2, 4, 8, 12 and 18

End point title	Open-Label Phase: Percentage of Subjects With JADAS CRP Inactive Disease Activity at Week 2, 4, 8, 12 and 18
End point description: JADAS inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthrititis: Inactive Disease: $\leq 1$ and 2) Oligoarthritis ( $< 4$ active joints): Inactive Disease: $\leq 1$ . Investigation of JADAS-27 score based on investigators and parent/legal/subjects assessment. OLJAS: all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.	
End point type	Secondary
End point timeframe: Week 2, 4, 8, 12 and 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: percentage of subjects				
number (not applicable)				
Week 2 (n= 183)	0			
Week 4 (n= 183)	0			
Week 8 (n= 176)	2.84			
Week 12 (n= 165)	3.64			
Week 18 (n= 154)	7.79			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Percentage of Subjects With JADAS CRP Inactive Disease Activity at Double Blind Baseline, Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Percentage of Subjects With JADAS CRP Inactive Disease Activity at Double Blind Baseline, Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

JADAS inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthrititis: Inactive Disease:  $\leq 1$  and 2) Oligoarthritis ( $< 4$  active joints): Inactive Disease:  $\leq 1$ . Investigation of JADAS-27 score based on investigators and parent/legal/subjects assessment. DBJAS: all subjects randomized to DB phase, received at least 1dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
----------------	-----------

End point timeframe:

Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)				
DB Baseline	6.94	10.00		
Week 20	9.72	2.86		
Week 24	12.50	5.71		
Week 28	9.72	7.14		
Week 32	11.11	5.71		
Week 36	16.67	7.14		
Week 40	18.06	7.14		
Week 44	18.06	10.00		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
----------------------------	--

Statistical analysis description:

Double Blind Baseline (Week 18)

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
-------------------	---



Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5131
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-3.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.21
upper limit	6.1

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0876
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	6.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.01
upper limit	14.74

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1561
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	6.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.59
upper limit	16.16

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5795
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	2.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.54
upper limit	11.7

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2435
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	5.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.67
upper limit	14.47

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0758
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	9.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.99
upper limit	20.04

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0464
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	10.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.17
upper limit	21.65

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1634
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	8.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.27
upper limit	19.38

## Secondary: Double Blind Phase: Percentage of Subjects With JIA ACR Inactive Disease at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Percentage of Subjects With JIA ACR Inactive Disease at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

JIA ACR Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the SUN Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 [no activity] to 10 [maximum activity]) score of 'best possible' on the scale used, morning stiffness of  $\leq 15$  minutes. DBJAS: all subjects randomized to DB phase, received at least 1dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)				
Week 20 (n= 71, 70)	15.28	15.71		
Week 24	20.83	21.43		
Week 28	19.44	18.57		
Week 32	22.22	20.00		
Week 36	26.39	17.14		
Week 40	26.39	14.29		
Week 44	26.39	17.14		
Double Blind Baseline (Week 18)	9.72	27.14		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
----------------------------	--

Statistical analysis description:

Week 18

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0062
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-17.42

Confidence interval	
level	95 %
sides	2-sided
lower limit	-29.88
upper limit	-4.96

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9427
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-0.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.34
upper limit	11.47

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9308
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.03
upper limit	12.84

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8945
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.03
upper limit	13.78

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7455
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	2.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.2
upper limit	15.64

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36	
Comparison groups	Placebo v Tofacitinib: Double Blind Phase
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1787
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	9.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.23
upper limit	22.72

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40	
Comparison groups	Placebo v Tofacitinib: Double Blind Phase
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0695
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	12.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.97
upper limit	25.17

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1787
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	9.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.23
upper limit	22.72

## Secondary: Double Blind Phase: Percentage of Subjects With Presence of JIA ACR Clinical Remission

End point title	Double Blind Phase: Percentage of Subjects With Presence of JIA ACR Clinical Remission
-----------------	--

End point description:

JIA ACR Clinical Remission Criteria included: Clinical inactive disease for 6 months continuously while on medications for JIA. Clinical Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the SUN Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 [no activity] to 10 [maximum activity]) score of 'best possible' (score of

"0") on the scale used, morning stiffness of less than or equal to ( $\leq$ ) 15 minutes. DBJAS: all subjects randomized to DB phase, received at least 1dose of study medication in DB phase and had polyarticular course JIA.

End point type	Secondary
End point timeframe:	
From Week 18 up to Week 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: percentage of subjects				
number (not applicable)	4.17	4.29		

## Statistical analyses

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9719
Method	Normal approximation to the binomial
Parameter estimate	Difference in percentage
Point estimate	-0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.74
upper limit	6.5

## Secondary: Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Active Arthritis at Week 2, 4, 8, 12 and 18

End point title	Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Active Arthritis at Week 2, 4, 8, 12 and 18
End point description:	
Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. The score range of the number of joints is from 0-71. OLJAS:all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 8, 12 and 18	



End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: joints				
arithmetic mean (standard deviation)				
Week 2 (n= 183)	-4.54 (± 5.33)			
Week 4 (n= 181)	-7.21 (± 6.36)			
Week 8 (n= 175)	-8.62 (± 7.04)			
Week 12 (n= 166)	-9.76 (± 6.76)			
Week 18 (n= 154)	-10.29 (± 6.79)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: JIA ACR Core Variable- Change from Double-Blind Baseline in Number of Joints With Active Arthritis at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: JIA ACR Core Variable- Change from Double-Blind Baseline in Number of Joints With Active Arthritis at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. Number of joints ranged from 0 to 71. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: joints				
least squares mean (standard error)				
Week 20 (n= 71, 70)	0.21 (± 0.48)	1.07 (± 0.49)		
Week 24 (n= 66, 60)	0.69 (± 0.71)	2.11 (± 0.72)		
Week 28 (n= 63, 50)	0.46 (± 0.61)	2.13 (± 0.64)		
Week 32 (n= 59, 45)	0.19 (± 0.48)	1.36 (± 0.51)		
Week 36 (n= 55, 37)	0.52 (± 0.85)	4.50 (± 0.92)		

Week 40 (n= 53, 35)	0.91 ( $\pm$ 0.85)	4.48 ( $\pm$ 0.93)		
Week 44 (n= 49, 33)	0.55 ( $\pm$ 0.74)	2.79 ( $\pm$ 0.77)		

## Statistical analyses

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1595
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.08
upper limit	0.35
Variability estimate	Standard error of the mean
Dispersion value	0.61

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1421
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-1.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.32
upper limit	0.48
Variability estimate	Standard error of the mean
Dispersion value	0.96

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0552
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-1.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.37
upper limit	0.04
Variability estimate	Standard error of the mean
Dispersion value	0.83

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0822
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-1.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	0.17
Variability estimate	Standard error of the mean
Dispersion value	0.63

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0041
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-3.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.53
upper limit	-1.43
Variability estimate	Standard error of the mean
Dispersion value	1.22

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0085
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-3.57
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.12
upper limit	-1.02
Variability estimate	Standard error of the mean
Dispersion value	1.22

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0384
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-2.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.36
upper limit	-0.13
Variability estimate	Standard error of the mean
Dispersion value	1.03

### Secondary: Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Limited Range of Motion at Week 2, 4, 8, 12 and 18

End point title	Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Limited Range of Motion at Week 2, 4, 8, 12 and 18
End point description:	The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'. OLJAS:all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.
End point type	Secondary
End point timeframe:	Baseline, Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: joints				
arithmetic mean (standard deviation)				
Week 2 (n= 183)	-2.52 (± 4.21)			
Week 4 (n= 181)	-3.56 (± 5.68)			
Week 8 (n= 175)	-4.53 (± 5.65)			
Week 12 (n= 166)	-5.09 (± 5.79)			
Week 18 (n= 154)	-5.77 (± 5.82)			

### Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Limited Range of Motion at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Limited Range of Motion at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: joints				
least squares mean (standard error)				
Week 20 (n= 71, 70)	0.38 (± 0.20)	0.64 (± 0.19)		
Week 24 (n= 66, 60)	0.50 (± 0.28)	1.19 (± 0.29)		
Week 28 (n= 63, 50)	0.68 (± 0.35)	1.63 (± 0.37)		
Week 32 (n= 59, 45)	0.61 (± 0.32)	1.40 (± 0.34)		
Week 36 (n= 55, 37)	0.47 (± 0.31)	1.48 (± 0.34)		
Week 40 (n= 53, 35)	0.41 (± 0.34)	1.49 (± 0.39)		
Week 44 (n= 49, 33)	0.38 (± 0.29)	1.20 (± 0.34)		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
----------------------------	--

Statistical analysis description:

Week 20: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the double-blind baseline value.

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2595
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-0.26

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.72
upper limit	0.19
Variability estimate	Standard error of the mean
Dispersion value	0.23

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Week 24: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the double-blind baseline value.

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0674
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-0.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.42
upper limit	0.05
Variability estimate	Standard error of the mean
Dispersion value	0.37

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Week 28: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the double-blind baseline value.

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.058
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.93
upper limit	0.03
Variability estimate	Standard error of the mean
Dispersion value	0.49

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the double-blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0751
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-0.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.67
upper limit	0.08
Variability estimate	Standard error of the mean
Dispersion value	0.44

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the double-blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0251
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.88
upper limit	-0.13
Variability estimate	Standard error of the mean
Dispersion value	0.43

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the double-blind baseline value.	



Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0331
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-1.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.07
upper limit	-0.09
Variability estimate	Standard error of the mean
Dispersion value	0.49

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44: Analysis was based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the double-blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0549
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.66
upper limit	0.02
Variability estimate	Standard error of the mean
Dispersion value	0.42

### **Secondary: Open Label Phase: JIA ACR Core Variable- Change From Baseline in Physician Global Evaluation of Disease Activity at Week 2, 4, 8, 12 and 18**

End point title	Open Label Phase: JIA ACR Core Variable- Change From Baseline in Physician Global Evaluation of Disease Activity at Week 2, 4, 8, 12 and 18
End point description:	
Physician global evaluation of disease activity was measured on a VAS (in millimetres) of 0 (no activity) to 10 (maximum activity), higher score indicated more disease activity. OLJAS:all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.	
End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: millimeters (mm)				
arithmetic mean (standard deviation)				
Week 2 (n= 183)	-1.81 (± 1.52)			
Week 4 (n= 181)	-2.78 (± 1.84)			
Week 8 (n= 175)	-3.51 (± 1.83)			
Week 12 (n= 166)	-4.04 (± 1.88)			
Week 18 (n= 154)	-4.54 (± 1.92)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: JIA ACR Core Variable-Change from Double-Blind Baseline in Physician Global Evaluation of Disease Activity at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: JIA ACR Core Variable-Change from Double-Blind Baseline in Physician Global Evaluation of Disease Activity at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

Physician global evaluation of disease activity was measured on a VAS (in millimetres) of 0 (no activity) to 10 (maximum activity), higher score indicated more disease activity. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: mm				
least squares mean (standard error)				
Week 20 (n= 71, 70)	0.28 (± 0.20)	0.82 (± 0.20)		
Week 24 (n= 66, 60)	0.24 (± 0.24)	1.08 (± 0.24)		
Week 28 (n= 63, 50)	0.12 (± 0.21)	0.92 (± 0.92)		
Week 32 (n= 59, 45)	-0.03 (± 0.20)	0.86 (± 0.22)		
Week 36 (n= 55, 37)	0.14 (± 0.28)	1.56 (± 0.32)		

Week 40 (n= 53, 35)	0.02 ( $\pm$ 0.28)	1.64 ( $\pm$ 0.32)		
Week 44 (n= 49, 33)	-0.16 ( $\pm$ 0.29)	1.42 ( $\pm$ 0.34)		

## Statistical analyses

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0353
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.04
upper limit	-0.04
Variability estimate	Standard error of the mean
Dispersion value	0.25

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0094
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.47
upper limit	-0.21
Variability estimate	Standard error of the mean
Dispersion value	0.32

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 28: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0065
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.36
upper limit	-0.23
Variability estimate	Standard error of the mean
Dispersion value	0.28

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0018
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.43
upper limit	-0.34
Variability estimate	Standard error of the mean
Dispersion value	0.27

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-1.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.24
upper limit	-0.61
Variability estimate	Standard error of the mean
Dispersion value	0.41

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-1.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.42
upper limit	-0.81
Variability estimate	Standard error of the mean
Dispersion value	0.4

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0007
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-1.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.44
upper limit	-0.71
Variability estimate	Standard error of the mean
Dispersion value	0.43

### Secondary: Open Label Phase: JIA ACR Core Variable- Change From Baseline in in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Week 2, 4, 8, 12 and 18

End point title	Open Label Phase: JIA ACR Core Variable- Change From Baseline in in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Week 2, 4, 8, 12 and 18
-----------------	--

#### End point description:

Parent/legal guardian/subject global assessment of overall well-being was assessed on a 0 to 10 mm horizontal VAS, where "0" represents 'very well' (i.e. symptom-free and no arthritis disease activity) and "10" represents 'very poor' (i.e. maximum arthritis disease activity). OLJAS:all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

#### End point timeframe:

Baseline, Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 2 (n= 182)	-0.94 (± 1.95)			
Week 4 (n= 181)	-1.47 (± 1.92)			
Week 8 (n= 175)	-1.90 (± 2.20)			
Week 12 (n= 165)	-2.30 (± 2.15)			
Week 18 (n= 154)	-2.68 (± 2.33)			

## Statistical analyses

**Secondary: Double Blind Phase: JIA ACR Core Variable- Change from Double-Blind Baseline in Double-Blind Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Week of Overall Well-Being at Week 20, 24, 28, 32, 36, 40 and 44**

End point title	Double Blind Phase: JIA ACR Core Variable- Change from Double-Blind Baseline in Double-Blind Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Week of Overall Well-Being at Week 20, 24, 28, 32, 36, 40 and 44
End point description:	Parent/legal guardian/subject global assessment of overall well-being was assessed on a 0 to 10 mm horizontal VAS, where "0" represents 'very well' (i.e. symptom-free and no arthritis disease activity) and "10" represents 'very poor' (i.e. maximum arthritis disease activity).DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.
End point type	Secondary
End point timeframe:	Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: Score on scale				
least squares mean (standard error)				
Week 20 (n= 71, 70)	-0.04 (± 0.18)	0.38 (± 0.18)		
Week 24 (n= 66, 60)	-0.03 (± 0.22)	0.91 (± 0.22)		
Week 28 (n= 63, 49)	-0.11 (± 0.24)	0.72 (± 0.26)		
Week 32 (n= 59, 45)	-0.15 (± 0.24)	0.82 (± 0.26)		
Week 36 (n= 55, 37)	-0.22 (± 0.21)	0.31 (± 0.24)		
Week 40 (n= 53, 35)	-0.24 (± 0.24)	0.39 (± 0.27)		
Week 44 (n= 49, 33)	-0.49 (± 0.22)	0.24 (± 0.24)		

**Statistical analyses**

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
	Week 20: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0398
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-0.42

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.83
upper limit	-0.02
Variability estimate	Standard error of the mean
Dispersion value	0.2

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Week 24: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0011
Method	MMRM
Parameter estimate	LS Mean difference
Point estimate	-0.94

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.49
upper limit	-0.39
Variability estimate	Standard error of the mean
Dispersion value	0.28

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Week 28: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0131
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.82

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.47
upper limit	-0.18
Variability estimate	Standard error of the mean
Dispersion value	0.32



<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 32: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0039
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.62
upper limit	-0.33
Variability estimate	Standard error of the mean
Dispersion value	0.32

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0711
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	0.05
Variability estimate	Standard error of the mean
Dispersion value	0.29

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0658
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.63
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	0.04
Variability estimate	Standard error of the mean
Dispersion value	0.34

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0154
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.31
upper limit	-0.15
Variability estimate	Standard error of the mean
Dispersion value	0.29

## **Secondary: Open Label Phase: JIA ACR Core Variable- Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Disability Index at Week 2, 4, 8, 12 and 18**

End point title	Open Label Phase: JIA ACR Core Variable- Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Disability Index at Week 2, 4, 8, 12 and 18
-----------------	--

### End point description:

CHAQ: parent-administered, valid assessment of functional disability, discomfort in pediatrics with rheumatic diseases. Parents report subjects ability to perform activities in 8 domains: dressing, arising, eating, walking, hygiene, each,grip, common activities distributed in total of 30 items. Each item is scored on 4-point Likert scale: 0=no difficulty; 1=some difficulty;2=much difficulty;3=unable to do. Highest score reported for domain is score for that domain. Overall score = sum of domain scores divided by number of domains answered. Total score: 0=no difficulty to 3=extreme difficulty, higher

score indicated more difficulty. OLJAS:all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 8, 12 and 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 2 (n= 182)	-0.15 (± 0.41)			
Week 4 (n= 181)	-0.23 (± 0.42)			
Week 8 (n= 175)	-0.36 (± 0.46)			
Week 12 (n= 165)	-0.41 (± 0.53)			
Week 18 (n= 154)	-0.49 (± 0.57)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: JIA ACR Core Variable- Change from Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Disability Index at Week 20, 24, 28, 32, 36, and 40

End point title	Double Blind Phase: JIA ACR Core Variable- Change from Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Disability Index at Week 20, 24, 28, 32, 36, and 40
-----------------	---

End point description:

CHAQ-DI: parent-administered, valid assessment of functional disability, discomfort in pediatrics with rheumatic diseases. Parents report participants's ability to perform activities in 8 domains: dressing, arising, eating, walking, hygiene, each, grip, common activities distributed in total of 30 items. Each item is scored on 4-point Likert scale: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Highest score reported for domain is score for that domain. The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, and 40	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: Score on scale				
least squares mean (standard deviation)				
Week 20 (n=71, 70 )	0.05 (± 0.04)	0.08 (± 0.04)		
Week 24 (n= 66, 59)	0.01 (± 0.03)	0.08 (± 0.04)		
Week 28 (n= 63, 49)	-0.01 (± 0.04)	0.09 (± 0.04)		
Week 32 (n=59, 45)	0.01 (± 0.04)	0.10 (± 0.05)		
Week 36 (n=55, 37)	-0.04 (± 0.04)	0.08 (± 0.05)		
Week 40 (n= 53, 35)	-0.05 (± 0.04)	0.06 (± 0.05)		

## Statistical analyses

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20: All MMRM models adjusted for OL baseline CRP category	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4777
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.12
upper limit	0.06
Variability estimate	Standard error of the mean
Dispersion value	0.04

Statistical analysis title	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0779
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.07

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.16
upper limit	0.01
Variability estimate	Standard error of the mean
Dispersion value	0.04

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Week 28: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0324
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.19
upper limit	-0.01
Variability estimate	Standard error of the mean
Dispersion value	0.05

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Week 32: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1061
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.09

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	0.02
Variability estimate	Standard error of the mean
Dispersion value	0.06

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 36: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0572
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.24
upper limit	0
Variability estimate	Standard error of the mean
Dispersion value	0.06

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0689
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.24
upper limit	0.01
Variability estimate	Standard error of the mean
Dispersion value	0.06

## **Secondary: Open-Label Phase: Change From Baseline in Child Health Questionnaire (CHQ) Responses at Week 4 and Week 18**

End point title	Open-Label Phase: Change From Baseline in Child Health Questionnaire (CHQ) Responses at Week 4 and Week 18
-----------------	--

End point description:

CHQ: 50-item,14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on parents. Each subscale rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Two summary scores: Physical Health, Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status. OLJAS:all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 4 and Week 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 4: Global Health (n= 171)	13.86 (± 22.40)			
Week 18: Global Health (n= 148)	21.28 (± 22.79)			
Week 4: Physical Functioning (n= 171)	11.83 (± 24.47)			
Week 18: Physical Functioning (n= 149)	21.44 (± 26.78)			
Week 4: Social Limitations: Emotional (n= 171)	8.12 (± 29.29)			
Week 18: Social Limitations: Emotional (n= 149)	14.62 (± 30.18)			
Week 4: Social Limitations: Physical (n= 171)	13.45 (± 31.12)			
Week 18: Social Limitations: Physical (n= 149)	20.81 (± 32.53)			
Week 4: Bodily Pain (n= 171)	19.42 (± 21.14)			
Week 18: Bodily Pain (n= 149)	30.60 (± 22.79)			
Week 4: Behavior (n= 171)	3.06 (± 12.86)			
Week 18: Behavior (n= 149)	5.70 (± 12.91)			
Week 4: Global Behavior (n= 171)	7.40 (± 23.27)			
Week 18: Global Behavior (n= 149)	9.30 (± 24.97)			
Week 4: Mental Health (n= 171)	6.43 (± 15.68)			
Week 18: Mental Health (n= 149)	6.74 (± 16.06)			
Week 4: Self Esteem (n= 171)	2.42 (± 19.47)			
Week 18: Self Esteem (n= 149)	8.45 (± 17.35)			
Week 4: Family Cohesion (n= 171)	2.78 (± 21.80)			
Week 18: Family Cohesion (n= 149)	3.62 (± 18.81)			
Week 4: General Health (n= 171)	4.20 (± 13.50)			
Week 18: General Health (n= 149)	7.02 (± 14.31)			
Week 4: Change in Health (n= 170)	0.86 (± 1.20)			

Week 18: Change in Health (n= 149)	1.70 (± 1.32)			
Week 4: Emotional Impact on Parent (n= 171)	9.02 (± 26.30)			
Week 18: Emotional Impact on Parent (n= 149)	15.38 (± 29.35)			
Week 4: Time Impact on Parent (n= 171)	6.17 (± 24.64)			
Week 18: Time Impact on Parent (n= 149)	9.99 (± 23.38)			
Week 4: Family Activities (n= 171)	5.19 (± 15.15)			
Week 18: Family Activities (n= 149)	9.59 (± 19.63)			
Week 4: Physical Summary Scores (n= 171)	8.12 (± 11.18)			
Week 18: Physical Summary Scores (n= 149)	13.36 (± 12.57)			
Week 4: Psychosocial Summary Scores (n= 171)	2.46 (± 8.13)			
Week 18: Psychosocial Summary Scores (n= 149)	4.20 (± 8.41)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Change From Double-Blind Baseline in Child Health Questionnaire (CHQ) Responses at Week 44

End point title	Double Blind Phase: Change From Double-Blind Baseline in Child Health Questionnaire (CHQ) Responses at Week 44
End point description:	
CHQ: 50-item,14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child’s physical, emotional, social well-being, and relative burden of disease on parents. Each subscale rated on Likert-type scale: range0 to 100; higher scores indicate more positive health status. 2 summary scores:Physical Health, Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status. DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA. “n” signifies subjects evaluable for this endpoint at specified time points.	
End point type	Secondary
End point timeframe:	
Double-Blind Baseline (Week 18), Week 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: Unit on scale				
least squares mean (standard error)				
Global Health (n= 49, 30)	5.46 (± 2.83)	1.66 (± 3.72)		
Physical Functioning (n= 49, 31)	1.45 (± 3.16)	-1.82 (± 3.92)		



Social Limitations: Emotional (n= 49, 31)	1.78 (± 3.53)	-3.69 (± 4.36)		
Social Limitations: Physical (n= 49, 30)	-3.08 (± 4.03)	-10.29 (± 5.04)		
Bodily Pain (n=49, 31)	6.34 (± 3.13)	-1.91 (± 3.91)		
Behavior (n= 49, 31)	0.78 (± 2.09)	4.20 (± 2.57)		
Global Behavior (n= 49, 31)	-2.61 (± 2.89)	1.04 (± 3.54)		
Mental Health (n= 49, 31)	0.41 (± 2.53)	3.88 (± 3.12)		
Self Esteem (n= 49, 31)	1.48 (± 3.29)	0.76 (± 4.07)		
General Health (n= 49, 31)	7.91 (± 1.84)	6.14 (± 2.26)		
Change in Health (n= 49, 31)	0.07 (± 0.10)	0.09 (± 0.12)		
Emotional Impact on Parent (n= 49, 31)	9.55 (± 4.32)	0.58 (± 5.35)		
Time Impact on Parent (n= 49, 30)	-3.83 (± 2.92)	2.89 (± 3.62)		
Family Activities (n= 49, 31)	0.01 (± 2.39)	8.61 (± 2.95)		
Family Cohesion (n= 49, 31)	6.04 (± 3.18)	3.45 (± 3.92)		
Physical Summary (n= 49, 30)	1.67 (± 1.48)	-1.81 (± 1.85)		
Psychosocial Summary (n= 49, 30)	0.64 (± 1.22)	1.39 (± 1.52)		

## Statistical analyses

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Global Health Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3179
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	3.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.72
upper limit	11.31
Variability estimate	Standard error of the mean
Dispersion value	3.77

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description: Physical Functioning Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4452
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	3.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.23
upper limit	11.78
Variability estimate	Standard error of the mean
Dispersion value	4.27

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Social Limitations: Emotional Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2539
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	5.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.01
upper limit	14.95
Variability estimate	Standard error of the mean
Dispersion value	4.76

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Social Limitations: Physical Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1981
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	7.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.86
upper limit	18.3
Variability estimate	Standard error of the mean
Dispersion value	5.56

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Bodily Pain Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.062
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	8.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	16.94
Variability estimate	Standard error of the mean
Dispersion value	4.36

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Behavior Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2291
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-3.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.06
upper limit	2.2
Variability estimate	Standard error of the mean
Dispersion value	2.83

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Global Behavior Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.353
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-3.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.43
upper limit	4.13
Variability estimate	Standard error of the mean
Dispersion value	3.9

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Mental Health Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3114
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-3.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.26
upper limit	3.32
Variability estimate	Standard error of the mean
Dispersion value	3.41

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Self Esteem Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8736
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.18
upper limit	9.61
Variability estimate	Standard error of the mean
Dispersion value	4.46

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
General Health Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4778
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	1.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.18
upper limit	6.72
Variability estimate	Standard error of the mean
Dispersion value	2.48

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Change in Health Subscale Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8909
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.28
upper limit	0.25
Variability estimate	Standard error of the mean
Dispersion value	0.13

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Emotional Impact on Parent Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.127
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	8.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.61
upper limit	20.55
Variability estimate	Standard error of the mean
Dispersion value	5.81

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Time Impact on Parent Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0944
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-6.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.62
upper limit	1.18
Variability estimate	Standard error of the mean
Dispersion value	3.96

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Family Activities Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
-------------------	---

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0095
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-8.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.03
upper limit	-2.17
Variability estimate	Standard error of the mean
Dispersion value	3.23

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Family Cohesion Subscale Standardized Score: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5474
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	2.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.96
upper limit	11.14
Variability estimate	Standard error of the mean
Dispersion value	4.29

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Physical Summary Scores: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo



Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0902
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	3.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.56
upper limit	7.52
Variability estimate	Standard error of the mean
Dispersion value	2.03

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Psychosocial Summary Scores: Analysis based on MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value.	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6539
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.07
upper limit	2.57
Variability estimate	Standard error of the mean
Dispersion value	1.67

### **Secondary: Open Label Phase: Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Week 2, 4, 8, 12 and 18**

End point title	Open Label Phase: Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Week 2, 4, 8, 12 and 18
-----------------	---

#### End point description:

CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/subject were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity. OLJAS:all subjects enrolled in OL phase and received at least 1 dose of medication in OL phase with polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 8, 12 and 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	184			
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 2 (n= 182)	-1.32 (± 2.10)			
Week 4 (n= 181)	-2.06 (± 2.16)			
Week 8 (n= 175)	-2.38 (± 2.40)			
Week 12 (n= 165)	-2.72 (± 2.28)			
Week 18 (n= 154)	-3.04 (± 2.57)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Week 20, 24, 28, 32, 36,40 and 44

End point title	Double Blind Phase: Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Week 20, 24, 28, 32, 36,40 and 44
-----------------	--

End point description:

CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/subject were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity.DBJAS: all subjects randomized to DB phase, received at least 1 dose of study medication in DB phase and had polyarticular course JIA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36,40 and 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	72	70		
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 20 (n= 71, 70)	0.08 (± 0.20)	0.40 (± 0.20)		

Week 24 (n= 66, 60)	-0.01 ( $\pm$ 0.24)	0.94 ( $\pm$ 0.24)		
Week 28 (n= 63, 49)	-0.23 ( $\pm$ 0.24)	0.64 ( $\pm$ 0.25)		
Week 32 (n= 59, 45)	0.07 ( $\pm$ 0.27)	1.06 ( $\pm$ 0.29)		
Week 36 (n= 55, 37)	-0.21 ( $\pm$ 0.21)	0.32 ( $\pm$ 0.24)		
Week 40 (n= 53, 35)	-0.22 ( $\pm$ 0.24)	0.49 ( $\pm$ 0.26)		
Week 44 (n= 49, 33)	-0.36 ( $\pm$ 0.23)	0.44 ( $\pm$ 0.25)		

## Statistical analyses

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 20: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1894
Method	MMRM
Parameter estimate	LS Mean Difference
Point estimate	-0.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.16
Variability estimate	Standard error of the mean
Dispersion value	0.24

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 24: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0026
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.56
upper limit	-0.34

Variability estimate	Standard error of the mean
Dispersion value	0.31

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Week 28: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0067
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	-0.25
Variability estimate	Standard error of the mean
Dispersion value	0.31

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:

Week 32: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value

Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0091
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.73
upper limit	-0.25
Variability estimate	Standard error of the mean
Dispersion value	0.37

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
-----------------------------------	--

Statistical analysis description:	
Week 36: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0632
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.09
upper limit	0.03
Variability estimate	Standard error of the mean
Dispersion value	0.28

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 40: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo
Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0306
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.35
upper limit	-0.07
Variability estimate	Standard error of the mean
Dispersion value	0.32

<b>Statistical analysis title</b>	Tofacitinib: Double Blind Phase Vs Placebo
Statistical analysis description:	
Week 44: The analysis was based on a MMRM with fixed effects of treatment, visit, JIA category, open-label baseline CRP, treatment-by-visit interaction, and the Double-Blind baseline value	
Comparison groups	Tofacitinib: Double Blind Phase v Placebo

Number of subjects included in analysis	142
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0118
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.41
upper limit	-0.18
Variability estimate	Standard error of the mean
Dispersion value	0.31

### Secondary: Open-Label Phase: Percentage of Subjects With Active Uveitis at Baseline

End point title	Open-Label Phase: Percentage of Subjects With Active Uveitis at Baseline
End point description:	
Uveitis is the inflammation of the uvea. Subjects were assessed for presence of uveitis (according to Standard Uveitis Nomenclature [SUN]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in subject at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported. OLFAS: all subjects who were enrolled into OL phase of the study and received at least one dose of study medication in OL phase.	
End point type	Secondary
End point timeframe:	
Baseline	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	225			
Units: percentage of subjects				
number (not applicable)				
Present	0.0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Percentage of Subjects With Active Uveitis at Week 24 and Week 44

End point title	Double Blind Phase: Percentage of Subjects With Active Uveitis at Week 24 and Week 44
End point description:	
Uveitis is the inflammation of the uvea. Subjects were assessed for presence of uveitis (according to Standard Uveitis Nomenclature [SUN]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in subject at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported. The double-blind safety analysis set (DBSAS): all subjects who have received at least one dose of study medication in double-blind phase.	
End point type	Secondary
End point timeframe:	
Weeks 24 and 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	88	85		
Units: percentage of subjects				
number (not applicable)				
Week 24: Present	0.0	1.2		
Week 44: Present	0.0	0.0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Open-Label Phase: Change from Baseline in the Tender Enthesal Assessment at Week 2, 4, 8, 12 and 18

End point title	Open-Label Phase: Change from Baseline in the Tender Enthesal Assessment at Week 2, 4, 8, 12 and 18
End point description:	
Subjects with enthesitis-related arthritis (ERA) undergo Tender enthesal assessment. Tender enthesal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66*(total number of tender entheses with counts > 0)/number of non-missing tender entheses. If > 33 tender enthesal counts were missing, total number of tender entheses was defined as missing. OLERA: all subjects who were enrolled into OL phase of study and received at least 1 dose of study medication in the OL phase with ERA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 8, 12 and 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Tender entheses				
arithmetic mean (standard deviation)				
Week 2 (n=21)	-1.57 (± 3.61)			
Week 4 (n=21)	-2.52 (± 3.92)			
Week 8 (n=20)	-3.05 (± 4.45)			
Week 12 (n=20)	-3.15 (± 4.93)			
Week 18 (n=20)	-3.50 (± 4.70)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Change from Double-Blind Baseline in the Tender Enthesal Assessment at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Change from Double-Blind Baseline in the Tender Enthesal Assessment at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	---

End point description:

Subjects with enthesitis-related arthritis (ERA) undergo Tender enthesal assessment. Tender enthesal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66\*(total number of tender entheses with counts > 0)/number of non-missing tender entheses. If > 33 tender enthesal counts were missing, total number of tender entheses was defined as missing. DBERA: all subjects randomized to the DB phase who received at least 1 dose of study medication in the DB phase with ERA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	7		
Units: Tender entheses				
arithmetic mean (standard deviation)				
Week 20 (n= 9, 7)	0.00 (± 0.87)	0.86 (± 2.61)		
Week 24 (n= 9, 5)	-1.00 (± 3.46)	0.40 (± 2.19)		
Week 28 (n= 7, 4)	-0.43 (± 2.57)	-0.75 (± 0.96)		
Week 32 (n= 6, 4)	0.33 (± 1.97)	0.00 (± 0.82)		
Week 36 (n= 6, 3)	-0.83 (± 2.04)	0.33 (± 0.58)		
Week 40 (n= 5, 3)	-2.00 (± 4.47)	0.33 (± 0.58)		
Week 44 (n= 5, 3)	-2.00 (± 5.66)	-0.33 (± 0.58)		



## Statistical analyses

No statistical analyses for this end point

### Secondary: Open-Label Phase: Change from Baseline in the Modified Schober's Test at Week 2, 4, 8, 12 and 18

End point title	Open-Label Phase: Change from Baseline in the Modified Schober's Test at Week 2, 4, 8, 12 and 18
-----------------	--

End point description:

Subjects with ERA undergo Modified Schober's Test. Modified Schober's Test: a) Measurement 10 cm above and 5 cm below the lumbosacral junction (the dimples of Venus) in the upright position. b) Measurement of the distance between the upper and the lower marks when the child is bending forward. OLERA: all subjects who were enrolled into OL phase of study and received at least 1 dose of study medication in the OL phase with ERA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Centimeter (cm)				
arithmetic mean (standard deviation)				
Week 2 (n= 16)	-0.35 (± 1.02)			
Week 4 (n= 15)	-0.20 (± 1.03)			
Week 8 (n= 16)	-0.12 (± 1.15)			
Week 12 (n= 16)	0.02 (± 1.05)			
Week 18 (n= 16)	0.29 (± 1.08)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Change from Baseline in the Modified Schober's Test at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Change from Baseline in the Modified Schober's Test at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	---

End point description:

Subjects with ERA undergo Modified Schober's Test. Modified Schober's Test: a) Measurement 10 cm above and 5 cm below the lumbosacral junction (the dimples of Venus) in the upright position. b)

Measurement of the distance between the upper and the lower marks when the child is bending forward.  
DBERA: all subjects randomized to the DB phase who received at least 1 dose of study medication in the DB phase with ERA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	7		
Units: cm				
arithmetic mean (standard deviation)				
Week 20 (n= 7, 5)	-0.46 (± 1.61)	-0.28 (± 0.47)		
Week 24 (n= 7, 4)	-0.44 (± 1.27)	-0.35 (± 0.54)		
Week 28 (n= 5, 3)	0.32 (± 1.38)	-0.17 (± 0.57)		
Week 32 (n= 4, 3)	0.42 (± 1.84)	0.63 (± 1.26)		
Week 36 (n= 3, 2)	-0.53 (± 0.84)	0.05 (± 0.21)		
Week 40 (n= 3, 2)	0.57 (± 1.62)	0.85 (± 0.64)		
Week 44 (n= 3, 2)	0.50 (± 0.87)	1.05 (± 2.47)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Open-Label Phase: Change from Baseline in the Overall Back Pain and Nocturnal Back Pain responses at Week 2, 4, 8, 12 and 18

End point title	Open-Label Phase: Change from Baseline in the Overall Back Pain and Nocturnal Back Pain responses at Week 2, 4, 8, 12 and 18
-----------------	--

End point description:

Subjects with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/subject were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/ subject using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain. OLERA: all subjects who were enrolled into OL phase of study and received at least 1 dose of study medication in the OL phase with ERA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 8, 12 and 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 2: Nocturnal Back Pain (n=21)	-1.21 ( $\pm$ 3.10)			
Week 4: Nocturnal Back Pain (n=21)	-1.33 ( $\pm$ 3.44)			
Week 8: Nocturnal Back Pain (n=20)	-1.80 ( $\pm$ 3.18)			
Week 12: Nocturnal Back Pain (n=20)	-2.30 ( $\pm$ 2.63)			
Week 18: Back Pain at Night (n=20)	-1.98 ( $\pm$ 2.94)			
Week 2: Overall back pain (n=21)	-1.81 ( $\pm$ 2.89)			
Week 4: Overall back pain (n=21)	-1.86 ( $\pm$ 3.29)			
Week 8: Overall back pain (n=20)	-2.65 ( $\pm$ 2.72)			
Week 12: Overall back pain (n=20)	-3.20 ( $\pm$ 2.54)			
Week 18: Overall back pain (n=20)	-3.30 ( $\pm$ 2.45)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Change from Double-Blind Baseline in the Overall Back Pain and Nocturnal Back Pain responses at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Change from Double-Blind Baseline in the Overall Back Pain and Nocturnal Back Pain responses at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

Subjects with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/subject were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/ subject using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain. DBERA: all subjects randomized to the DB phase who received at least 1 dose of study medication in the DB phase with ERA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	7		
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 20: Nocturnal Back Pain (n= 9, 7)	-0.17 ( $\pm$ 0.87)	0.57 ( $\pm$ 0.93)		
Week 24: Nocturnal Back Pain (n= 9, 5)	-1.06 ( $\pm$ 1.96)	0.10 ( $\pm$ 0.42)		
Week 28: Nocturnal Back Pain(n= 7, 4)	-0.79 ( $\pm$ 2.00)	0.00 ( $\pm$ 0.41)		

Week 32: Nocturnal Back Pain (n= 6,4)	-1.58 (± 1.63)	0.38 (± 0.63)		
Week 36: Nocturnal Back Pain (n= 6,3)	-0.75 (± 2.27)	0.17 (± 0.29)		
Week 40: Nocturnal Back Pain (n= 5, 3)	-2.00 (± 2.26)	0.17 (± 0.29)		
Week 44: Nocturnal Back Pain(n= 5, 3)	-0.80 (± 2.20)	0.17 (± 0.29)		
Week 20: Overall back pain (n= 9, 7)	0.28 (± 1.89)	0.57 (± 1.40)		
Week 24: Overall back pain (n= 9, 5)	0.39 (± 2.10)	0.00 (± 0.79)		
Week 28:Overall back pain (n= 7, 4)	0.00 (± 2.60)	-0.25 (± 0.29)		
Week 32: Overall back pain (n= 6, 4)	-1.75 (± 2.25)	-0.13 (± 0.48)		
Week 36: Overall back pain (n= 6, 3)	0.17 (± 1.29)	-0.50 (± 0.87)		
Week 40: Overall back pain (n= 5, 3)	0.30 (± 1.79)	-0.50 (± 0.87)		
Week 44: Overall back pain (n= 5, 3)	-0.10 (± 3.45)	-0.50 (± 0.87)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Open-Label Phase: Changes From Baseline in Percentage of Body Surface Area (BSA) Affected with Psoriasis at Weeks 2, 4, 8, 12 and 18

End point title	Open-Label Phase: Changes From Baseline in Percentage of Body Surface Area (BSA) Affected with Psoriasis at Weeks 2, 4, 8, 12 and 18
-----------------	--

End point description:

Percentage of body surface area affected by psoriasis was estimated using the palm method: one of the participant's palm to proximal interphalangeal (PIP) and thumb = 1% of BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% [10 palms], Upper extremities = 20% [20 palms], Trunk [axillae and groin] = 30% [30 palms], Lower extremities [buttocks] = 40% [40 palms]) The total BSA affected was the summation of individual regions affected. OLPSa: all subjects who were enrolled into the OL phase of study and received at least 1 dose of study medication in OL phase with PsA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Percentage of BSA				
arithmetic mean (standard deviation)				
Week 2 (n=20)	0.55 (± 4.70)			
Week 4 (n=19)	-1.03 (± 2.49)			
Week 8 (n=17)	-0.29 (± 6.11)			
Week 12 (n=18)	-0.36 (± 5.93)			
Week 18 (n=16)	-0.46 (± 6.48)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Changes From Double Blind Baseline in Percentage of Body Surface Area (BSA) Affected with Psoriasis at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Changes From Double Blind Baseline in Percentage of Body Surface Area (BSA) Affected with Psoriasis at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	---

End point description:

Percentage of body surface area affected by psoriasis was estimated using the palm method: one of the participant's palm to PIP and thumb = 1% of BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% [10 palms], Upper extremities = 20% [20 palms], Trunk [axillae and groin] = 30% [30 palms], Lower extremities [buttocks] = 40% [40 palms]) The total BSA affected was the summation of individual regions affected. DBPsA: all subjects randomized to the DB phase who received at least 1 dose of study medication in the DB phase with PsA. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	8		
Units: Percentage of BSA				
arithmetic mean (standard deviation)				
Week 20 (n= 6, 8)	-0.50 (± 1.22)	0.28 (± 0.70)		
Week 24 (n= 7, 8)	-0.14 (± 0.38)	0.85 (± 1.71)		
Week 28 (n= 5, 3)	-4.20 (± 8.84)	0.33 (± 0.58)		
Week 32 (n= 5, 3)	-0.60 (± 1.34)	1.67 (± 2.89)		
Week 36 (n= 5, 3)	-4.20 (± 8.90)	1.33 (± 2.31)		
Week 40 (n= 5, 3)	-4.60 (± 8.71)	0.67 (± 1.15)		
Week 44 (n= 5, 2)	-4.60 (± 8.71)	-0.05 (± 0.07)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Open-Label Phase: Changes From Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Week 2, 4, 8, 12 and 18

End point title	Open-Label Phase: Changes From Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Week 2, 4, 8, 12 and 18
-----------------	--

End point description:

PsA assessed PGA of psoriasis. The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 5 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0=

no evidence to 5=sever, higher score indicates more severity. OLPsA: all subjects who were enrolled into the OL phase of study and received at least 1 dose of study medication in OL phase with PsA. Here, "n" signifies subjects evaluable for this end point at specified time points.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 8, 12 and 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	20			
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 2 (n= 20)	-0.05 (± 0.39)			
Week 4 (n= 19)	-0.42 (± 0.84)			
Week 8 (n= 17)	-0.29 (± 0.92)			
Week 12 (n= 18)	-0.56 (± 0.86)			
Week 18 (n= 16)	-0.56 (± 1.03)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Changes From Double-Blind Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Week 20, 24, 28, 32, 36, 40 and 44

End point title	Double Blind Phase: Changes From Double-Blind Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Week 20, 24, 28, 32, 36, 40 and 44
-----------------	--

End point description:

PsA assessed PGA of psoriasis. The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 5 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0= no evidence to 5=sever, higher score indicates more severity. DBPsA: all subjects randomized to the DB phase who received at least 1 dose of study medication in the DB phase with PsA. Here, "n" signifies subjects evaluable for this end point at specified time points.

End point type	Secondary
End point timeframe:	
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44	

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	8		
Units: Score on scale				
arithmetic mean (standard deviation)				
Week 20 (n= 7, 8)	0.14 (± 0.38)	0.00 (± 0.00)		
Week 24 (n= 7, 8)	0.14 (± 0.38)	0.38 (± 0.52)		
Week 28 (n= 5, 3)	0.20 (± 0.45)	0.33 (± 0.58)		
Week 32 (n= 5, 3)	0.00 (± 0.00)	0.33 (± 0.58)		
Week 36 (n= 5, 3)	0.00 (± 0.00)	0.33 (± 0.58)		
Week 40 (n= 5, 3)	0.00 (± 0.00)	0.00 (± 0.00)		
Week 44 (n= 5, 2)	0.00 (± 0.00)	-0.50 (± 0.71)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Open-Label Phase: Taste Assessment of Tofacitinib Oral Solution on Day 14

End point title	Open-Label Phase: Taste Assessment of Tofacitinib Oral Solution on Day 14
-----------------	---

End point description:

Oral solution was used in subjects weighing less than (<) 40 kilogram (kg) and in subjects who are unable to swallow tablets. Taste acceptability was assessed by asking the subjects to select one of several choices which reflects the subject's response to taste. Taste acceptability assessment response included: dislike Very Much, dislike a Little, Not Sure, like a little and like Very Much. OLFAS: all subjects who were enrolled into OL phase and received at least 1 dose of study medication in OL phase . Here, Number of subjects analysed signifies subjects who were evaluable for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 14

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	84			
Units: subjects				
Dislike Very Much	4			
Dislike a Little	8			
Not Sure	6			
Like a Little	32			
Like Very Much	34			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Open-Label Phase: Number of Subjects With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases

End point title	Open-Label Phase: Number of Subjects With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases
-----------------	---

End point description:

Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts:  $<500$  lymphocytes/mm<sup>3</sup> (mm), neutrophil counts  $<1000$  neutrophils/mm<sup>3</sup>, platelet counts  $<100,000$  platelets/mm<sup>3</sup>, any single hemoglobin value  $<8$  grams/decilitre (g/dL) and any single hemoglobin value drops  $\geq 2$  g/dL below baseline. Number of Subjects with serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported. OLFAS: all subjects who were enrolled into OL phase and received at least 1 dose of study medication in OL phase

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study drug up to week 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	225			
Units: subjects				
Serious Infections	3			
Cytopenia: Lymphocyte counts $<500$ lymphocytes/mm <sup>3</sup>	1			
Cytopenia:Neutrophil counts $<1000$ neutrophils/mm <sup>3</sup>	4			
Cytopenia:Platelet counts $<100,000$ platelets/mm <sup>3</sup>	1			
Cytopenia:Any single hemoglobin value $<8$ g/dL	1			
Cytopenia:Any hg value drops $\geq 2$ g/dL below baseline	17			
Malignancies	0			
Cardiovascular Diseases	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Number of Subjects With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases

End point title	Double Blind Phase: Number of Subjects With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases
-----------------	---



**End point description:**

Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts: <500 lymphocytes/ millimeter<sup>3</sup> (mm), neutrophil counts <1000 neutrophils/mm<sup>3</sup>, platelet counts <100,000 platelets/mm<sup>3</sup>, any single hemoglobin value <8 grams/decilitre (g/dL) and any single hemoglobin value drops  $\geq 2$  g/dL below baseline. Number of Subjects with serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported. DBFAS: all subjects randomized to DB phase who received at least 1 dose of study medication in DB phase.

End point type	Secondary
----------------	-----------

End point timeframe:

Screening up to week 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	88	85		
Units: subjects				
Serious Infections	0	1		
Cytopenia: Lymphocyte counts <500 lymphocytes/mm <sup>3</sup>	0	0		
Cytopenia:Neutrophil counts <1000 neutrophils/mm <sup>3</sup>	0	2		
Cytopenia:Platelet counts <100,000 platelets/mm <sup>3</sup>	1	0		
Cytopenia:Any single hemoglobin value <8 g/dL	0	0		
Cytopenia:Any hg value drops $\geq 2$ g/dL below baseline	3	7		
Malignancies	0	0		
Cardiovascular Diseases	0	0		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Open-Label Phase: Number of Subjects With Tanner Staging Evaluation (Pubic Hair)**

End point title	Open-Label Phase: Number of Subjects With Tanner Staging Evaluation (Pubic Hair)
-----------------	--

**End point description:**

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Day 1 was summarized and reported using number of subjects in each stage. OLFAS: all subjects who were enrolled into OL phase and received at least 1 dose of study medication in OL phase. Here, Number of subjects analyzed signifies subjects who were evaluable for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	218			
Units: subjects				
Stage 1	73			
Stage 2	21			
Stage 3	25			
Stage 4	47			
Stage 5	52			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Number of Subjects With Tanner Staging Evaluation (Pubic Hair)

End point title	Double Blind Phase: Number of Subjects With Tanner Staging Evaluation (Pubic Hair)
-----------------	--

End point description:

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Week 44 was summarized and reported using number of subjects in each stage. DB safety analysis set (DBSAS): all subjects who have received atleast 1 dose of study medication in DB phase. Here, Number of subjects analyzed signifies subjects who were evaluable for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	56	38		
Units: subjects				
Stage 1	13	7		
Stage 2	8	7		
Stage 3	8	3		
Stage 4	14	4		

Stage 5	13	17		
---------	----	----	--	--

## Statistical analyses

No statistical analyses for this end point

## Secondary: Open-Label Phase: Number of Subjects With Tanner Staging Evaluation (Breast Exam)

End point title	Open-Label Phase: Number of Subjects With Tanner Staging Evaluation (Breast Exam)
End point description:	
Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. OLFAS: all subjects who were enrolled into OL phase and received at least 1 dose of study medication in OL phase. Here, Number of subjects analyzed signifies subjects who were evaluable for this end point.	
End point type	Secondary
End point timeframe:	
Day 1	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	163			
Units: subjects				
Stage 1	42			
Stage 2	19			
Stage 3	28			
Stage 4	34			
Stage 5	40			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Number of Subjects With Tanner Staging Evaluation (Breast Exam)

End point title	Double Blind Phase: Number of Subjects With Tanner Staging Evaluation (Breast Exam)
-----------------	---

---

**End point description:**

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. DBSAS: all subjects who have received at least 1 dose of study medication in DB phase. Here, Number of subjects analyzed signifies subjects who were evaluable for this end point.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Week 44

---

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	43	28		
Units: subjects				
Stage 1	6	8		
Stage 2	8	2		
Stage 3	7	2		
Stage 4	13	3		
Stage 5	9	13		

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Open-Label Phase: Number of Subjects With Tanner Staging Evaluation (Genitalia)**

---

End point title	Open-Label Phase: Number of Subjects With Tanner Staging Evaluation (Genitalia)
-----------------	---

---

End point description:

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume < 4 ml or long axis < 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: > 20 ml (or > 4.5 cm long). Tanner Stage for genitalia at Day 1 was summarized and reported using number of subjects in each stage. OLFAS: all subjects who were enrolled into OL phase and received at least 1 dose of study medication in OL phase. Here, Number of subjects analyzed signifies subjects who were evaluable for this end point.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Day 1

---

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	55			
Units: subjects				
Stage 1	24			
Stage 2	6			
Stage 3	8			
Stage 4	11			
Stage 5	6			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Number of Subjects With Tanner Staging Evaluation (Genitalia)

End point title	Double Blind Phase: Number of Subjects With Tanner Staging Evaluation (Genitalia)
-----------------	---

End point description:

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume < 4 ml or long axis < 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: > 20 ml (or > 4.5 cm long). Tanner Stage for genitalia at Day 1 was summarized and reported using number of subjects in each stage. DBSAS: all subjects who have received at least 1 dose of study medication in DB phase. Here, Number of subjects analyzed signifies subjects who were evaluable for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	10		
Units: subjects				
Stage 1	5	0		
Stage 2	0	5		
Stage 3	2	0		
Stage 4	5	1		
Stage 5	1	4		

## Statistical analyses

**Secondary: Open-Label Phase: Number of Subjects With Laboratory Abnormalities**

End point title	Open-Label Phase: Number of Subjects With Laboratory Abnormalities
End point description:	
Hematology: Hemoglobin(Hg),hematocrit erythrocytes(Ery); <0.8*lower limit of normal (LLN), Ery. Mean Corpuscular Volume; <0.9*LLN, >1.1*ULN (Upper LN), Platelets; <0.5*LLN, >1.75*ULN, Leukocytes (leu); <0.6*LLN, >1.5*ULN, Lymphocytes (Ly), Ly/leu, Neutrophils, Neutrophils/leu <0.8*LLN, Basophils/leu, Eosinophils, Eosinophils/leu, Monocytes, Monocytes/leu >1.2*ULN, Ery Sedimentation Rate >1.5*ULN. Chemistry: Bilirubin, Indirect Bilirubin >1.5*ULN, AST, ALT, Gamma Glutamyl Transferase, Alkaline Phosphatase >3.0*ULN, Albumin >1.2*ULN, Creatinine >1.3*ULN, HDL Cholesterol (Chol)<0.8*LLN, LDL Chol, LDL Chol Friedewald Est PEG >1.2*ULN, Triglycerides >1.3*ULN, Calcium <0.9*LLN, Bicarbonate <0.9*LLN, Glucose >1.5*ULN, Creatine Kinase >2.0*ULN, C Reactive Protein >1.1*ULN, Chol >1.3*ULN. OLFAS analysis population used for this endpoint. 'n'=subjects evaluable for this endpoint at specified time points.Only those category in which at least 1 subject data reported.	
End point type	Secondary
End point timeframe:	
From the first dose of study drug up to Week 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	225			
Units: subjects				
Hemoglobin (<0.8* LLN) (n= 224)	1			
Hematocrit (<0.8* LLN) (n= 224)	1			
Erythrocytes (<0.8* LLN)(n= 224)	2			
Ery. Mean Corpuscular Volume (<0.9*LLN) (n= 224)	3			
Ery. Mean Corpuscular Volume (>1.1*ULN ) (n= 224)	4			
Platelets (<0.5*LLN) (n= 224)	1			
Platelets (>1.75*ULN) (n= 224)	2			
Leukocytes (<0.6*LLN) (n= 224)	1			
Leukocytes (>1.5*ULN) (n= 224)	2			
Lymphocytes (<0.8*LLN)(n= 224)	7			
Lymphocytes (>1.2*ULN) (n= 224)	2			
Lymphocytes/Leu.( <0.8*LLN) (n= 224)	15			
Lymphocytes/Leu.( >1.2*ULN) (n= 224)	20			
Neutrophils (<0.8*LLN) (n= 224)	8			
Neutrophils (>1.2*ULN) (n= 224)	18			
Neutrophils/Leu. (<0.8*LLN) (n= 224)	19			
Basophils/Leu.( >1.2*ULN) (n= 224)	37			
Eosinophils (>1.2*ULN) (n= 224)	53			
Eosinophils/Leu.( >1.2*ULN) (n= 224)	32			
Monocytes (>1.2*ULN) (n= 224)	3			
Monocytes/Leu. (>1.2*ULN) (n= 224)	38			
Ery. Sedimentation Rate (>1.5*ULN)(n= 224)	65			
Bilirubin (>1.5*ULN) (n= 225)	1			

Indirect Bilirubin (>1.5*ULN) (n= 225)	1			
AST (>3.0*ULN) (n= 225)	4			
ALT(>3.0*ULN) (n= 225)	5			
GGT (>3.0*ULN) (n= 225)	1			
Alkaline Phosphatase (>3.0*ULN)(n= 225)	1			
Albumin (>1.2*ULN) (n= 225)	1			
Creatinine (>1.3*ULN) (n= 225)	1			
HDL Cholesterol (<0.8*LLN) (n= 223)	2			
LDL Cholesterol (>1.2*ULN) (n= 87)	4			
LDL Chol Friedewald Est PEG (>1.2*ULN) (n= 222)	1			
Triglycerides(>1.3*ULN) (n= 222)	27			
Calcium (<0.9*LLN) (n= 225)	1			
Bicarbonate (<0.9*LLN) (n= 225)	10			
Glucose (>1.5*ULN) (n= 225)	2			
Creatine Kinase (>2.0*ULN) (n= 224)	12			
C Reactive Protein (>1.1*ULN) (n= 225)	122			
Cholesterol (>1.3*ULN) (n= 223)	2			
Specific Gravity >1.030 (n= 225)	32			
URINE Glucose(>1.030) (n= 225)	1			
Ketones (>=1) (n= 225)	11			
URINE Protein (>=1)(n= 225)	9			
URINE Hemoglobin (>=1) (n= 225)	48			
Nitrite (>=1) (n= 225)	6			
Leukocyte Esterase (>=1) (n= 225)	59			
URINE Erythrocytes (>=1) (n= 113)	23			
URINE Leukocytes (>=20) (n= 150)	16			
Hyaline Casts (>=1) (n= 3)	1			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Number of Subjects With Laboratory Abnormalities

End point title	Double Blind Phase: Number of Subjects With Laboratory Abnormalities
-----------------	--

End point description:

Hematology: Hg,Hematocrit Ery; <0.8\*LLN,Ery. Mean Corpuscular Volume; <0.9\*LLN, >1.1\*ULN, Platelets; <0.5\*LLN, Leu ; <0.6\*LLN, >1.5\*ULN, Lymphocytes >1.2\*ULN, Lymphocytes/ Leu, Neutrophils, Neutrophils/Leu>1.2\*ULN and <0.8\*LLN,Basophils, Basophils/Leu, Eosinophils, Eosinophils/Leukocytes, Monocytes, Monocytes/Leu >1.2\*ULN, Prothrombin Time >1.1\*ULN, Erythrocyte Sedimentation Rate >1.5\*ULN. Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin >1.5\*ULN, ALT, AST, GGT >3.0\*ULN,HDL Chol <0.8\*LLN,Triglycerides >1.3\*ULN, Potassium >1.1x ULN, Calcium, <0.9\*LLN, Glucose >1.5\*ULN, Bicarbonate <0.9\*LLN, Creatine Kinase >2.0\*ULN, C Reactive Protein >1.1\*ULN. Urinalysis: Specific Gravity >1.030, pH >8, urine Glucose, Ketones, Protein, Hg, Nitrite, Leukocyte Esterase >=1, Ery, Leukocytes >=20, Hyaline Casts >1. Only those category in which at least 1 subject data reported.DBSAS analysis population used for this endpoint. 'n'=subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study drug in double blind up to Week 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	88	85		
Units: subjects				
Hg. (<0.8*LLN) (n= 87, 85)	1	3		
Hematocrit (<0.8*LLN) (n= 87, 85)	0	2		
Ery. (<0.8*LLN) (n= 87, 85)	0	2		
Ery. Mean Corpuscular Volume(<0.9*LLN)(n= 87, 85)	2	1		
Ery. Mean Corpuscular Volume (>1.1*ULN)(n= 87, 85)	1	2		
Platelets(<0.5*LLN) (n= 88, 84)	1	0		
Leu. (<0.6*LLN) (n= 87, 85)	0	1		
Leu.(>1.5*ULN)(n= 87, 85)	1	0		
Lymphocytes(<0.8*LLN) (n= 87, 85)	5	1		
Lymphocytes(>1.2*ULN)(n= 87, 85)	1	0		
Lymphocytes/Leu. (<0.8*LLN) (n= 87, 85)	9	5		
Lymphocytes/Leu.(>1.2*ULN) (n= 87, 85)	5	7		
Neutrophils(<0.8*LLN) (n= 87, 85)	1	3		
Neutrophils(>1.2*ULN) (n= 87, 85)	7	5		
Neutrophils/Leu.(<0.8*LLN)(n= 87, 85)	5	6		
Basophils(>1.2*ULN) (n= 87, 85)	1	0		
Basophils/Leu.(>1.2*ULN) (n= 87, 85)	14	15		
Eosinophils(>1.2*ULN) (n= 87, 85)	27	18		
Eosinophils/Leu.(>1.2*ULN) (n= 87, 85)	21	14		
Monocytes(>1.2*ULN) (n= 87, 85)	2	2		
Monocytes/Leu.(>1.2*ULN) (n= 87, 85)	18	19		
Prothrombin Time (>1.1*ULN)(n= 3, 2)	0	1		
Ery. Sedimentation Rate (>1.5*ULN) (n= 88, 85)	26	19		
Bilirubin (>1.5*ULN) (n= 88, 85)	1	0		
Direct Bilirubin (>1.5*ULN) (n= 88, 85)	1	0		
Indirect Bilirubin (>1.5*ULN)(n= 88, 85)	1	0		
Alanine Aminotransferase (>3.0*ULN)(n= 88, 85)	1	2		
GGT(>3.0*ULN) (n= 88, 85)	1	0		
HDL Cholesterol (<0.8*LLN) (n= 70, 61)	0	2		
Triglycerides(>1.3*ULN) (n= 71, 61)	8	6		
Potassium (>1.1*ULN) (n= 88, 85)	1	0		
Calcium (<0.9*LLN ) (n= 88, 85)	1	1		
Glucose (>1.5*ULN) (n= 88, 85)	1	0		
Creatine Kinase(>2.0*ULN) (n= 88, 85)	2	2		
C Reactive Protein(>1.1*ULN) (n= 88, 85)	44	47		
Specific Gravity (>1.030)(n= 88, 85)	12	7		



pH (>8) (n= 88, 85)	0	1		
URINE Glucose (>=1) (n= 88, 85)	1	1		
Ketones (>=1) (n= 88, 85)	7	10		
URINE Protein (>=1) (n= 88, 85)	4	4		
URINE Hemoglobin (>=1) (n= 88, 85)	25	11		
Nitrite (>=1) (n= 88, 85)	3	6		
Leu. Esterase (>=1) (n= 88, 85)	26	25		
URINE Ery.(>=20) (n= 51, 41)	10	6		
URINE Leu. (>=20) (n= 66, 57)	6	6		
Hyaline Casts (>1)(n= 2, 1)	1	1		
Granular Casts (>1)(n=0,1)	0	1		
Bicarbonate(<0.9*LLN) (n=88,85)	0	2		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Open-Label Phase: Number of Subjects With Physical Examination Abnormalities

End point title	Open-Label Phase: Number of Subjects With Physical Examination Abnormalities
-----------------	--

End point description:

Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion. OLFAS: all subjects who were enrolled into OL phase and received at least 1 dose of study medication in OL phase. 'n'=subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 8, 12 and 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	225			
Units: subjects				
Abdomen: Baseline	1			
Abdomen: Week 2	2			
Abdomen: Week 4	3			
Abdomen: Week 8	2			
Abdomen: Week 12	2			
Abdomen: Week 18	1			
Ears: Baseline	5			
Ears: Week 2	0			
Ears: Week 4	0			
Ears: Week 8	0			
Ears: Week 12	0			
Ears: Week 18	3			

Extremities: Baseline	49			
Extremities: Week 2	43			
Extremities: Week 4	35			
Extremities: Week 8	30			
Extremities: Week 12	28			
Extremities: Week 18	23			
Eyes: Baseline	2			
Eyes: Week 2	0			
Eyes: Week 4	0			
Eyes: Week 8	0			
Eyes: Week 12	0			
Eyes: Week 18	2			
General appearance: Baseline	16			
General appearance: Week 2	0			
General appearance: Week 4	1			
General appearance: Week 8	2			
General appearance: Week 12	0			
General appearance: Week 18	5			
Head: Baseline	3			
Head: Week 2	0			
Head: Week 4	0			
Head: Week 8	0			
Head: Week 12	0			
Head: Week 18	4			
Heart: Baseline	0			
Heart: Week 2	0			
Heart: Week 4	0			
Heart: Week 8	2			
Heart: Week 12	0			
Heart: Week 18	0			
Lungs: Baseline	1			
Lungs: Week 2	1			
Lungs: Week 4	0			
Lungs: Week 8	1			
Lungs: Week 12	1			
Lungs: Week 18	0			
Lymph nodes: Baseline	2			
Lymph nodes: Week 2	5			
Lymph nodes: Week 4	5			
Lymph nodes: Week 8	5			
Lymph nodes: Week 12	3			
Lymph nodes: Week 18	4			
Neurological: Baseline	4			
Neurological: Week 2	1			
Neurological: Week 4	0			
Neurological: Week 8	0			
Neurological: Week 12	0			
Neurological: Week 18	4			
Nose: Baseline	0			
Nose: Week 2	0			
Nose: Week 4	0			
Nose: Week 8	0			

Nose: Week 12	0			
Nose: Week 18	5			
Skin: Baseline	27			
Skin: Week 2	0			
Skin: Week 4	1			
Skin: Week 8	1			
Skin: Week 12	0			
Skin: Week 18	12			
Throat: Baseline	1			
Throat: Week 2	0			
Throat: Week 4	0			
Throat: Week 8	0			
Throat: Week 12	0			
Throat: Week 18	6			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Double Blind Phase: Number of Subjects With Physical Examination Abnormalities

End point title	Double Blind Phase: Number of Subjects With Physical Examination Abnormalities
-----------------	--

End point description:

Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion. DBSAS: all subjects who have received atleast 1 dose of study medication in DB phase. Here, 'n'=subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 18, 20, 24, 28, 32, 36, 40 and 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	88	85		
Units: subjects				
Abdomen: Week 18 (n= 88, 84)	0	1		
Abdomen: Week 20 (n= 87, 85)	1	1		
Abdomen: Week 24 (n= 82, 73)	1	1		
Abdomen: Week 28 (n= 75, 57)	0	0		
Abdomen: Week 32 (n= 70, 52)	0	0		
Abdomen: Week 36 (n= 66, 43)	0	0		
Abdomen: Week 40 (n= 63, 41)	0	0		
Abdomen: Week 44 (n= 59, 38)	0	0		
Ears: Week 18 (n= 88, 84)	3	0		
Ears: Week 20 (n= 4, 5)	0	0		

Ears: Week 24 (n= 5, 5)	0	0		
Ears: Week 28 (n= 2, 2)	0	0		
Ears: Week 32 (n= 2, 3)	0	0		
Ears: Week 40 (n= 1, 1)	0	1		
Ears: Week 44 (n= 59, 38)	0	0		
Extremities: Week 18 (n= 88, 84)	9	12		
Extremities: Week 20 (n= 87, 85)	11	14		
Extremities: Week 24 (n= 82, 73)	5	7		
Extremities: Week 28 (n= 75, 57)	6	6		
Extremities: Week 32 (n= 70, 52)	1	8		
Extremities: Week 36 (n= 66, 43)	2	6		
Extremities: Week 40 (n= 63, 41)	3	6		
Extremities: Week 44 (n= 59, 38)	3	7		
Eyes: Week 18 (n= 88, 84)	2	0		
Eyes: Week 20 (n= 4, 5)	0	0		
Eyes: Week 24 (n= 5, 5)	0	0		
Eyes: Week 28 (n= 2, 2)	0	0		
Eyes: Week 32 (n= 2, 3)	0	0		
Eyes: Week 40 (n= 1,1)	0	0		
Eyes: Week 44 (n= 59, 38)	1	0		
General appearance: Week 18 (n= 88, 84)	2	3		
General appearance: Week 20 (n= 4, 5)	1	1		
General appearance: Week 24 (n= 5, 5)	0	0		
General appearance: Week 28 (n= 2, 2)	0	0		
General appearance: Week 32 (n= 2, 3)	0	0		
General appearance: Week 40 (n= 1, 1)	0	0		
General appearance: Week 44 (n= 59, 38)	1	0		
Head: Week 18 (n= 88, 84)	3	1		
Head: Week 20 (n= 4, 5)	0	0		
Head: Week 24 (n= 5,5)	0	0		
Head: Week 28 (n= 2, 2)	0	0		
Head: Week 32 (n= 2, 3)	0	1		
Head: Week 40 (n= 1, 1)	1	0		
Head: Week 44 (n= 59, 38)	0	0		
Heart: Week 18 (n= 88, 84)	0	0		
Heart: Week 20 (n= 87, 85)	0	0		
Heart: Week 24 (n= 82, 73)	0	0		
Heart: Week 28 (n= 75, 57)	0	0		
Heart: Week 32 (n= 70, 52)	0	0		
Heart: Week 36 (n= 66, 43)	0	0		
Heart: Week 40 (n= 63, 41)	0	0		
Heart: Week 44 (n= 59, 38)	0	0		
Lungs: Week 18 (n= 88, 84)	0	0		
Lungs: Week 20 (n= 87, 85)	1	0		
Lungs: Week 24 (n= 82, 73)	1	0		
Lungs: Week 28 (n= 75, 57)	1	0		
Lungs: Week 32 (n= 70, 52)	0	0		
Lungs: Week 36 (n= 66, 43)	0	0		
Lungs: Week 40 (n= 63, 41)	0	1		
Lungs: Week 44 (n= 59, 38)	0	0		

Lymph nodes: Week 18 (n= 88, 84)	3	1		
Lymph nodes: Week 20 (n= 87, 85)	3	0		
Lymph nodes: Week 24 (n= 82, 73)	2	1		
Lymph nodes: Week 28 (n= 75, 57)	1	0		
Lymph nodes: Week 32 (n= 70, 52)	1	1		
Lymph nodes: Week 36 (n= 66, 43)	1	0		
Lymph nodes: Week 40 (n= 63, 41)	2	0		
Lymph nodes: Week 44 (n= 59, 38)	1	1		
Neurological: Week 18 (n= 88, 85)	3	1		
Neurological: Week 20 (n= 4, 5)	1	0		
Neurological: Week 24 (n= 5, 5)	0	0		
Neurological: Week 28 (n= 2, 2)	0	0		
Neurological: Week 32 (n= 2,3)	0	0		
Neurological: Week 40 (n= 1, 1)	0	0		
Neurological: Week 44 (n= 59, 38)	1	1		
Nose: Week 18 (n= 88, 84)	4	0		
Nose: Week 20 (n= 4, 5)	0	0		
Nose: Week 24 (n= 5, 5)	0	0		
Nose: Week 28 (n= 2, 2)	0	0		
Nose: Week 32 (n= 2, 3)	0	0		
Nose: Week 40 (n= 1, 1)	0	0		
Nose: Week 44 (n= 59, 38)	1	0		
Skin: Week 18 (n= 88, 84)	8	4		
Skin: Week 20 (n= 4, 5)	3	1		
Skin: Week 24 (n= 5, 5)	1	0		
Skin: Week 28 (n= 2,2)	0	0		
Skin: Week 32 (n= 2, 3)	0	0		
Skin: Week 40 (n= 1, 1)	1	1		
Skin: Week 44 (n= 59, 38)	4	2		
Throat: Week 18 (n= 88, 84)	4	2		
Throat: Week 20 (n= 4, 5)	0	1		
Throat: Week 24 (n= 5, 5)	0	0		
Throat: Week 28 (n= 2, 2)	0	0		
Throat: Week 32 (n= 2, 3)	0	0		
Throat: Week 40 (n= 1, 1)	0	0		
Throat: Week 44 (n= 59, 38)	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Open-Label Phase: Number of Subjects With Vital Sign Abnormalities

End point title	Open-Label Phase: Number of Subjects With Vital Sign Abnormalities
-----------------	--

End point description:

Vital Sign Abnormalities criteria included: sitting diastolic blood pressure (mmHg) of <50 mmHg, sitting pulse rate beats per minute (bpm) of <40 or 120 bpm, sitting systolic blood pressure (MMHG) of <90 mmHg, supine diastolic blood pressure (mmHg) of <50 mmHg, supine pulse rate (BPM) of <40 bpm or >120 bpm, supine systolic blood pressure (mmHg) of 90 mmHg. OLFAS: all subjects who were enrolled into OL phase and received at least 1 dose of study medication in OL phase. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
End point timeframe:	
From the first dose of study drug up to Week 18	

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	225			
Units: subjects				
Sitting diastolic BP: <50 mmHg (n= 219)	0			
Sitting pulse rate: <40 bpm (n= 219)	0			
Sitting pulse rate (bpm): >120 bpm (n= 219)	5			
Sitting systolic BP (mmHg): <90 mmHg (n= 219)	0			
Supine diastolic BP (mmHg): <50 mmHg (n= 28)	2			
Supine pulse rate (bpm): <40 bpm (n= 28)	0			
Supine pulse rate (bpm): >120 bpm (n= 28)	0			
Supine systolic BP (mmHg): <90 mmHg (n= 28)	2			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Number of Subjects With Vital Sign Abnormalities

End point title	Double Blind Phase: Number of Subjects With Vital Sign Abnormalities
-----------------	--

End point description:

Vital Sign Abnormalities criteria included: diastolic blood pressure (mmHG) of <50 mmHg, Pulse rate (BPM) of <40 bpm or >120 bpm, sitting diastolic blood pressure (mmHG) of <50 mmHg, sitting pulse rate beats per minute (bpm) of <40 bpm or >120 bpm, sitting systolic blood pressure (mmHG) of <90 mmHg, supine diastolic blood pressure (MMHG) of <50 mmHg, supine pulse rate (BPM) of <40 bpm or >120 bpm, supine systolic blood pressure (mmHG) of <90 mmHg, systolic blood pressure (mmHG) of <90 mmHg. DBSAS: all subjects who have received atleast 1 dose of study medication in DB phase. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study drug in double blind up to week 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87	82		
Units: subjects				
Diastolic BP (mmHg): <50 mmHg (n=1, 0)	0	0		
Pulse rate (bpm): <40 bpm (n=1, 0)	0	0		
Pulse rate (bpm): >120 bpm (n=1, 0)	0	0		
Systolic BP (mmHg): <90 mmHg (n=86, 82)	0	0		
Sitting diastolic BP (mmHg): <50 mmHg (n=86, 82)	0	0		
Sitting pulse rate (bpm): <40 bpm (n=86, 82)	0	0		
Sitting pulse rate (bpm): >120 bpm (n=87, 82)	0	1		
Sitting systolic BP (mmHg): <90 mmHg (n=7, 8)	0	0		
Supine diastolic BP (mmHg): <50 mmHg (n=7, 8)	0	0		
Supine pulse rate (bpm): <40 bpm (n=7, 8)	0	0		
Supine pulse rate (bpm): >120 bpm (n=7, 8)	0	0		
Supine systolic BP (mmHg): <90 mmHg (n=1, 0)	1	0		
Systolic BP (mmHg): <90 mmHg (n=1, 0)	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Open-Label Phase: Number of Subjects With Change From Baseline in Vital Sign Measures

End point title	Open-Label Phase: Number of Subjects With Change From Baseline in Vital Sign Measures
-----------------	---

End point description:

Change in vital Signs included: Sitting diastolic blood pressure [mmHg]:  $\geq 20$  mmHg increase from baseline (IFB) and  $\geq 20$  mmHg decrease from baseline (DFB). Sitting systolic blood pressure mmHg:  $\geq 30$  mmHg IFB and  $\geq 30$  mmHg DFB. Supine diastolic blood pressure mmHg:  $\geq 20$  mmHg IFB and  $\geq 20$  mmHg DFB. Supine systolic blood pressure mmHg:  $\geq 30$  mmHg IFB and  $\geq 30$  mmHg DFB. OLFAS: all subjects who were enrolled into OL phase and received at least 1 dose of study medication in OL phase. Here, "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study drug up to Week 18

End point values	Tofacitinib: Open-Label Phase			
Subject group type	Reporting group			
Number of subjects analysed	225			
Units: subjects				
Sitting diastolic BP:Chg $\geq$ 20mmHg increase(n=211)	9			
Sitting diastolic BP:Chg $\geq$ 20mmHg decrease(n=211)	14			
Sitting systolic BP:Chg $\geq$ 30mmHg increase(n=211)	2			
Sitting systolic BP:Chg $\geq$ 30mmHg decrease(n=211)	5			
Supine diastolic BP: Chg $\geq$ 20mmHg increase (n=14)	0			
Supine diastolic BP: Chg $\geq$ 20mmHg decrease (n=14)	3			
Supine systolic BP: Chg $\geq$ 30mmHg increase (n=14)	0			
Supine systolic BP: Chg $\geq$ 30mmHg decrease (n=14)	3			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Double Blind Phase: Number of Subjects With Change From Baseline in Vital Sign Measures

End point title	Double Blind Phase: Number of Subjects With Change From Baseline in Vital Sign Measures
-----------------	---

End point description:

Change in vital Signs included: Sitting diastolic blood pressure (mmHG):  $\geq$ 20mmHg IFB and  $\geq$  20mmHg DFB. Sitting systolic blood pressure mmHG:  $\geq$  30mmHg IFB and  $\geq$  30mmHg DFB. Supine diastolic blood pressure mmHG:  $\geq$  20mmHg IFB and  $\geq$  20mmHg DFB. Supine systolic blood pressure mmHG:  $\geq$  30mmHg IFB and  $\geq$  30mmHg DFB. DBSAS: all subjects who have received atleast 1 dose of study medication in DB phase. Here, N= subjects who were evaluable for this endpoint and "n" signifies subjects evaluable for this endpoint at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study drug in double blind up to week 44

End point values	Tofacitinib: Double Blind Phase	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87	80		
Units: subjects				
Sitting diastolic BP:Chg $\geq$ 20 Increase (n=82, 79)	9	3		
Sitting diastolic BP:Chg $\geq$ 20 decrease (n=82, 79)	7	9		



Sitting systolic BP: Chg >= 30 Increase (n=83, 79)	3	4		
Sitting systolic BP: Chg >= 30 decrease (n=83, 79)	0	2		
Supine diastolic BP: Chg >= 20 Increase (n=4, 5)	0	0		
Supine diastolic BP: Chg >= 20 decrease(n=4, 5)	0	0		
Supine systolic BP: Chg >= 30 Increase (n=4, 5)	0	0		
Supine systolic BP: Chg >= 30 decrease(n=4, 5)	0	0		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From the first dose of study drug up to week 44

Adverse event reporting additional description:

Same event may appear as AE and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 subject and as nonserious in another subject or 1 subject may have experienced both serious and nonserious event during study.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

### Reporting groups

Reporting group title	Tofacitinib: Double Blind Phase
-----------------------	---------------------------------

Reporting group description:

Subjects who completed open-label phase and achieved at least a JIA ACR 30 response in open label phase, were randomized at Week 18 to receive tofacitinib tablets (for subjects  $\geq 40$  body weight) or oral solution (for subjects  $< 40$  kg body weight), BID, in double-blind phase for additional 26 weeks (up to Week 44).

Reporting group title	Tofacitinib: Open-Label Phase
-----------------------	-------------------------------

Reporting group description:

Subjects received tofacitinib 5 mg tablets (for subjects  $\geq 40$  kg body weight) or tofacitinib 5 mL oral solution (for subjects  $< 40$  kg body weight), BID, orally for 18 weeks in open-label phase.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects who completed open-label phase and achieved at least a JIA ACR 30 response in open label phase, were randomized at Week 18 to receive placebo either as oral tablets, (for subjects  $\geq 40$  body weight) or oral solution (for subjects  $< 40$  kg body weight), BID, in double-blind phase for additional 26 weeks (up to Week 44).

Serious adverse events	Tofacitinib: Double Blind Phase	Tofacitinib: Open-Label Phase	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 88 (1.14%)	7 / 225 (3.11%)	2 / 85 (2.35%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Surgical and medical procedures			
Pilonidal sinus repair			
subjects affected / exposed	1 / 88 (1.14%)	0 / 225 (0.00%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Condition aggravated			

subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
Crohn's disease			
subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			
subjects affected / exposed	0 / 88 (0.00%)	0 / 225 (0.00%)	1 / 85 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
Still's disease			
subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Juvenile idiopathic arthritis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 225 (0.00%)	1 / 85 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Appendicitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	1 / 85 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Epidural empyema			
subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subperiosteal abscess			
subjects affected / exposed	0 / 88 (0.00%)	1 / 225 (0.44%)	0 / 85 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

<b>Non-serious adverse events</b>	Tofacitinib: Double Blind Phase	Tofacitinib: Open-Label Phase	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	57 / 88 (64.77%)	108 / 225 (48.00%)	57 / 85 (67.06%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	3 / 88 (3.41%)	6 / 225 (2.67%)	2 / 85 (2.35%)
occurrences (all)	4	7	2
Aspartate aminotransferase increased			
subjects affected / exposed	4 / 88 (4.55%)	7 / 225 (3.11%)	1 / 85 (1.18%)
occurrences (all)	4	8	1
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 88 (3.41%)	5 / 225 (2.22%)	1 / 85 (1.18%)
occurrences (all)	3	5	1
C-reactive protein increased			

subjects affected / exposed occurrences (all)	1 / 88 (1.14%) 1	0 / 225 (0.00%) 0	2 / 85 (2.35%) 2
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 88 (0.00%) 0	0 / 225 (0.00%) 0	2 / 85 (2.35%) 2
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 88 (0.00%) 0	0 / 225 (0.00%) 0	2 / 85 (2.35%) 2
Nervous system disorders Headache subjects affected / exposed occurrences (all)	2 / 88 (2.27%) 2	16 / 225 (7.11%) 21	6 / 85 (7.06%) 8
General disorders and administration site conditions Disease progression subjects affected / exposed occurrences (all)	8 / 88 (9.09%) 8	5 / 225 (2.22%) 5	13 / 85 (15.29%) 13
Pyrexia subjects affected / exposed occurrences (all)	4 / 88 (4.55%) 5	11 / 225 (4.89%) 11	1 / 85 (1.18%) 1
Condition aggravated subjects affected / exposed occurrences (all)	2 / 88 (2.27%) 2	0 / 225 (0.00%) 0	2 / 85 (2.35%) 2
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 88 (0.00%) 0	5 / 225 (2.22%) 5	0 / 85 (0.00%) 0
Leukopenia subjects affected / exposed occurrences (all)	0 / 88 (0.00%) 0	0 / 225 (0.00%) 0	2 / 85 (2.35%) 2
Lymphadenitis subjects affected / exposed occurrences (all)	1 / 88 (1.14%) 1	0 / 225 (0.00%) 0	2 / 85 (2.35%) 2
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	2 / 88 (2.27%) 2	0 / 225 (0.00%) 0	1 / 85 (1.18%) 1

Eye disorders			
Uveitis			
subjects affected / exposed	0 / 88 (0.00%)	0 / 225 (0.00%)	2 / 85 (2.35%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 88 (0.00%)	5 / 225 (2.22%)	0 / 85 (0.00%)
occurrences (all)	0	5	0
Nausea			
subjects affected / exposed	0 / 88 (0.00%)	13 / 225 (5.78%)	0 / 85 (0.00%)
occurrences (all)	0	13	0
Abdominal pain			
subjects affected / exposed	0 / 88 (0.00%)	8 / 225 (3.56%)	3 / 85 (3.53%)
occurrences (all)	0	8	3
Diarrhoea			
subjects affected / exposed	1 / 88 (1.14%)	5 / 225 (2.22%)	2 / 85 (2.35%)
occurrences (all)	1	6	2
Vomiting			
subjects affected / exposed	0 / 88 (0.00%)	12 / 225 (5.33%)	4 / 85 (4.71%)
occurrences (all)	0	14	5
Dyspepsia			
subjects affected / exposed	2 / 88 (2.27%)	0 / 225 (0.00%)	1 / 85 (1.18%)
occurrences (all)	2	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 88 (2.27%)	7 / 225 (3.11%)	1 / 85 (1.18%)
occurrences (all)	3	9	2
Epistaxis			
subjects affected / exposed	3 / 88 (3.41%)	0 / 225 (0.00%)	1 / 85 (1.18%)
occurrences (all)	3	0	1
Nasal congestion			
subjects affected / exposed	2 / 88 (2.27%)	0 / 225 (0.00%)	1 / 85 (1.18%)
occurrences (all)	2	0	1
Oropharyngeal pain			
subjects affected / exposed	2 / 88 (2.27%)	0 / 225 (0.00%)	3 / 85 (3.53%)
occurrences (all)	2	0	3

Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	2 / 88 (2.27%)	0 / 225 (0.00%)	0 / 85 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 88 (2.27%)	5 / 225 (2.22%)	4 / 85 (4.71%)
occurrences (all)	2	5	4
Arthritis			
subjects affected / exposed	1 / 88 (1.14%)	0 / 225 (0.00%)	3 / 85 (3.53%)
occurrences (all)	1	0	3
Back pain			
subjects affected / exposed	3 / 88 (3.41%)	5 / 225 (2.22%)	1 / 85 (1.18%)
occurrences (all)	3	6	1
Juvenile idiopathic arthritis			
subjects affected / exposed	3 / 88 (3.41%)	6 / 225 (2.67%)	11 / 85 (12.94%)
occurrences (all)	3	6	11
Pain in extremity			
subjects affected / exposed	1 / 88 (1.14%)	0 / 225 (0.00%)	2 / 85 (2.35%)
occurrences (all)	1	0	3
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	2 / 88 (2.27%)	0 / 225 (0.00%)	0 / 85 (0.00%)
occurrences (all)	2	0	0
Influenza			
subjects affected / exposed	3 / 88 (3.41%)	8 / 225 (3.56%)	2 / 85 (2.35%)
occurrences (all)	3	8	2
Nasopharyngitis			
subjects affected / exposed	7 / 88 (7.95%)	10 / 225 (4.44%)	3 / 85 (3.53%)
occurrences (all)	7	14	3
Pharyngitis			
subjects affected / exposed	2 / 88 (2.27%)	5 / 225 (2.22%)	1 / 85 (1.18%)
occurrences (all)	2	5	1
Pharyngitis streptococcal			
subjects affected / exposed	2 / 88 (2.27%)	5 / 225 (2.22%)	0 / 85 (0.00%)
occurrences (all)	3	5	0

Respiratory tract infection subjects affected / exposed occurrences (all)	3 / 88 (3.41%) 3	0 / 225 (0.00%) 0	1 / 85 (1.18%) 1
Respiratory tract infection viral subjects affected / exposed occurrences (all)	1 / 88 (1.14%) 1	0 / 225 (0.00%) 0	2 / 85 (2.35%) 2
Rhinitis subjects affected / exposed occurrences (all)	2 / 88 (2.27%) 2	0 / 225 (0.00%) 0	1 / 85 (1.18%) 1
Sinusitis subjects affected / exposed occurrences (all)	4 / 88 (4.55%) 4	0 / 225 (0.00%) 0	1 / 85 (1.18%) 1
Tonsillitis subjects affected / exposed occurrences (all)	1 / 88 (1.14%) 1	0 / 225 (0.00%) 0	2 / 85 (2.35%) 2
Upper respiratory tract infection subjects affected / exposed occurrences (all)	13 / 88 (14.77%) 15	24 / 225 (10.67%) 30	9 / 85 (10.59%) 10
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 88 (1.14%) 1	0 / 225 (0.00%) 0	3 / 85 (3.53%) 3
Viral infection subjects affected / exposed occurrences (all)	2 / 88 (2.27%) 3	5 / 225 (2.22%) 5	1 / 85 (1.18%) 1
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	0 / 88 (0.00%) 0	6 / 225 (2.67%) 6	0 / 85 (0.00%) 0



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Data not reported for the PK endpoint, since the PK dataset will be combined with PK from other studies to enable the analysis, the results of this pooled analysis will be reported separately.
--

Notes: